Tumors or cancer of the URINARY BLADDER.
A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
Pathological processes of the URINARY BLADDER.
Stones in the URINARY BLADDER; also known as vesical calculi, bladder stones, or cystoliths.
The epithelial lining of the URINARY TRACT.
Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands.
Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES.
A substituted carcinogenic nitrosamine.
Discharge of URINE, liquid waste processed by the KIDNEY, from the body.
The duct which coveys URINE from the pelvis of the KIDNEY through the URETERS, BLADDER, and URETHRA.
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.
Endoscopic examination, therapy or surgery of the urinary bladder.
Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.
Passage of a CATHETER into the URINARY BLADDER or kidney.
Unstriated and unstriped muscle, one of the muscles of the internal organs, blood vessels, hair follicles, etc. Contractile elements are elongated, usually spindle-shaped cells with centrally located nuclei. Smooth muscle fibers are bound together into sheets or bundles by reticular fibers and frequently elastic nets are also abundant. (From Stedman, 25th ed)
Inability to empty the URINARY BLADDER with voiding (URINATION).
Used for excision of the urinary bladder.
The mechanical laws of fluid dynamics as they apply to urine transport.
A species of the true toads, Bufonidae, becoming fairly common in the southern United States and almost pantropical. The secretions from the skin glands of this species are very toxic to animals.
The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA.
Presence of blood in the urine.
Low-density crystals or stones in any part of the URINARY TRACT. Their chemical compositions often include CALCIUM OXALATE, magnesium ammonium phosphate (struvite), CYSTINE, or URIC ACID.
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
An abnormal passage in the URINARY BLADDER or between the bladder and any surrounding organ.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Persons living in the United States having origins in any of the black groups of Africa.
Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.
Chemical substances that are foreign to the biological system. They include naturally occurring compounds, drugs, environmental agents, carcinogens, insecticides, etc.
Individuals whose ancestral origins are in the continent of Europe.
Tumors or cancer of the URINARY TRACT in either the male or the female.
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases.
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
The interactions between physician and patient.
Those individuals engaged in research.
Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; SPONTANEOUS ABORTION; INDUCED ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO.
Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.
Rare congenital disorder of connective tissue characterized by brachydactyly, joint stiffness, childhood onset of ocular abnormalities (e.g., microspherophakia, ECTOPIA LENTIS; GLAUCOMA), and proportionate short stature. Cardiovascular anomalies are occasionally seen.
Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)

Long-term transplantability and morphological stability of three experimentally induced urinary bladder carcinomas in rats. (1/4713)

Three transitional cell carcinomas induced in Fischer 344 rats by a methylcholanthrene pellet or a foreign body inserted locally into the bladder have been serially transplanted in the syngeneic strain for up to 6.5 years. There have been no changes in the individual morphological characteristics of the tumors during this time. Cells cultured in vitro for varying numbers of passages reproduce regularly the morphology of each tumor when they are injected back into the animals and results from a microcytotoxicity assay for cellular immunity indicate that they retain a common, bladder tumor-specific antigen. These tumors are useful for research in turmo biology and are offered to other scientists seeking transplantable carcinomas for experimentation.  (+info)

Natural history of papillary lesions of the urinary bladder in schistosomiasis. (2/4713)

Variable epithelial hyperplasia was observed in urinary bladder of nine capuchin monkeys (Cebus apella) when examined at cystotomy 94 to 164 weeks after infection with Schistosoma haematobium. These hosts were followed for 24 to 136 weeks postcystotomy to determine the status of bladder lesions in relation to duration of infection and to ascertain whether lesion samples removed at cystotomy reestablished themselves in autologous and heterologous transfers. There was involution of urothelial hyperplasia in eight of nine animals and no evidence for establishment of transplanted bladder lesions.  (+info)

Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. (3/4713)

The evolution of alterations on chromosome 9, including the putative tumor suppressor genes mapped to the 9p21-22 region (the MTS genes), was studied in relation to the progression of human urinary bladder neoplasia by using whole organ superimposed histologic and genetic mapping in cystectomy specimens and was verified in urinary bladder tumors of various pathogenetic subsets with longterm follow-up. The applicability of chromosome 9 allelic losses as non-invasive markers of urothelial neoplasia was tested on voided urine and/or bladder washings of patients with urinary bladder cancer. Although sequential multiple hits in the MTS locus were documented in the development of intraurothelial precursor lesions, the MTS genes do not seem to represent a major target for p21-23 deletions in bladder cancer. Two additional tumor suppressor genes involved in bladder neoplasia located distally and proximally to the MTS locus within p22-23 and p11-13 regions respectively were identified. Several distinct putative tumor suppressor gene loci within the q12-13, q21-22, and q34 regions were identified on the q arm. In particular, the pericentromeric q12-13 area may contain the critical tumor suppressor gene or genes for the development of early urothelial neoplasia. Allelic losses of chromosome 9 were associated with expansion of the abnormal urothelial clone which frequently involved large areas of urinary bladder mucosa. These losses could be found in a high proportion of urothelial tumors and in voided urine or bladder washing samples of nearly all patients with urinary bladder carcinoma.  (+info)

Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. (4/4713)

Recent studies have shown that patients whose bladder cancer exhibit overexpression of RB protein as measured by immunohistochemical analysis do equally poorly as those with loss of RB function. We hypothesized that loss of p16 protein function could be related to RB overexpression, since p16 can induce transcriptional downregulation of RB and its loss may lead to aberrant RB regulation. Conversely, loss of RB function has been associated with high p16 protein expression in several other tumor types. In the present study RB negative bladder tumors also exhibited strong nuclear p16 staining while each tumor with strong, homogeneous RB nuclear staining were p16 negative, supporting our hypothesis. To expand on these immunohistochemical studies additional cases were selected in which the status of the p16 encoding gene had been determined at the molecular level. Absent p16 and high RB protein expression was found in the tumors having loss of heterozygosity within 9p21 and a structural change (mutation or deletion) of the remaining p16 encoding gene allele, confirming the staining results. These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with loss of p16 function and implies that loss of p16 function could be equally deleterious as RB loss in bladder and likely other cancers.  (+info)

Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. (5/4713)

The Mdm2 protein is frequently overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the bladder where it may contribute to tolerance of wtp53. Mdm2 forms an autoregulatory feedback loop with p53; the Mdm2 gene is responsive to transactivation by p53 and once synthesized the Mdm2 protein terminates the p53 response. We show here that the topoisomerase poison etoposide, like ultra violet irradiation, inhibits Mdm2 synthesis. Cytotoxic concentrations of etoposide (IC90 for > 3 h) result in inhibition of Mdm2 induction at both the RNA and protein level. Rapid apoptosis ensues. Global transcription is not inhibited: p21waf-1/cip1 and GADD45 expression increase in a dose dependent manner. Inhibition of Mdm2 synthesis depends on the continuous presence of etoposide, suggesting the DNA damage may prevent transcription. Downregulation of Mdm2 transcript occurs in cells expressing HPV16-E6 suggesting that inhibition of Mdm2 transcription is p53-independent. When cells are -treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated. Induction of apoptosis and loss of clonogenicity are 3-5-fold lower under pulse treatment conditions. This is the first observation of inhibition of Mdm2 transcription following treatment with topoisomerase (topo II) poisons, a feature that may be useful in tumour types where p53 is tolerated by overexpression of Mdm2.  (+info)

Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. (6/4713)

Interleukin (IL)-10 is a potent immunosuppressive cytokine that has been found to be present at the tumor site in a wide variety of human cancers, including transitional cell carcinoma of the bladder. Using a murine bladder tumor (MB49), which we show to express the male transplantation antigen (HY), we tested the hypothesis that IL-10 at the tumor site can block the generation of a tumor-specific type 1 immune response. We show that, despite its expression of HY, MB49 fails to prime for an HY-specific type 1 (IFN-gamma) response in normal female mice. Although MB49 does not constitutively produce IL-10, our data support a model whereby MB49 induces infiltrating cells to produce IL-10. This feature rendered the IL-10 knockout (KO) mouse, whose infiltrating cells are incapable of IL-10 production, a suitable model in which to study MB49 in the absence of IL-10. When injected into IL-10 KO mice, MB49 does prime for an HY-specific, type 1 immune response. Furthermore, IL-10 KO mice show prolonged survival and an increased capacity to reject tumors as compared with normal mice. We also tested the ability of tumor-induced IL-10 to inhibit immunization to a non-tumor antigen present at the tumor site. When vaccinia virus encoding beta-galactosidase (beta-gal) is injected into the tumors of normal mice, no beta-gal-specific IFN-gamma response is mounted. However, when this same viral construct is injected into the tumors of IL-10 KO mice, it produces a strong beta-gal-specific, IFN-gamma response. These studies demonstrate that tumor-induced IL-10 can block the generation of a tumor-specific type 1 immune response as well as subvert attempts to elicit a type 1 immune response to a non-tumor antigen at the tumor site.  (+info)

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. (7/4713)

Epidermal growth factor receptor (EGFR) regulates the growth and progression of human transitional cell carcinoma (TCC) of the bladder. We have shown that therapy targeting EGFR inhibited the growth of human TCC established orthotopically in nude mice. The purpose of this study was to evaluate whether EGFR-directed therapy affects angiogenesis associated with the growth and metastasis of human TCC. We determined the cytostatic effect and the effect on production of angiogenic factors after in vitro treatment of the human TCC cell line 253J B-V with MAb C225, a chimerized monoclonal anti-EGFR antibody. The 253J B-V cells were implanted orthotopically into athymic nude mice, and established tumors (4 weeks) were treated with i.p. MAb C225. Expression of the angiogenic factors vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and basic fibroblast growth factor (bFGF) was evaluated by immunohistochemistry and in situ mRNA hybridization analyses and correlated with microvessel density evaluated after immunohistochemical staining with anti-CD31. In vitro treatment with MAb C225 inhibited mRNA and protein production of VEGF, IL-8, and bFGF by 253J B-V cells in a dose-dependent manner. MAb C225 therapy of nude mice with established TCCs growing orthotopically resulted in inhibition of growth and metastasis compared with controls (P <0.0005). VEGF, IL-8, and bFGF expression was significantly lower in treated tumors than in controls. The down-regulation of these angiogenic factors preceded the involution of blood vessels. These studies indicate that therapy with anti-EGFR MAb C225 has a significant antitumor effect mediated, in part, by inhibition of angiogenesis.  (+info)

Vaginal epithelioid angiosarcoma. (8/4713)

A case of epithelioid angiosarcoma of the vagina is described. Only five cases of angiosarcoma at this site have been reported, three of which followed radiotherapy for other gynaecological malignancies. None is described as an epithelioid angiosarcoma, an unusual and recently described variant which is readily confused with carcinoma. This is thought to be the first reported epithelioid angiosarcoma at this site and highlights the difficulties in diagnosis.  (+info)

Mutation induction at the hypoxanthine-guanine phosphoribosyl transferase (hprt) locus has been studied in three human bladder tumour cell lines of varying radiosensitivity. U1-S40b, a radiosensitive mutant clone of MGH-U1, has been previously reported to show no difference in split-dose recovery or low dose-rate sparing, but to have an impaired repair fidelity when compared to its parent line. In this paper we have shown that U1-S40b is less mutable at the hprt locus at a similar level of survival. This may represent an increased incidence of severe or non-repairable lesions, making hprt- mutants poorly recoverable in U1-S40b when compared to MGH-U1. No difference was seen in mutation induction between MGH-U1 and RT112, another human bladder tumour cell line of similar radiosensitivity to MGH-U1.. ...
DelveInsight has launched a new report on Non Muscle Invasive Bladder Cancer Pipeline. Non-muscle invasive bladder cancer (NMIBC) formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.. Request for free sample copy- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight Non Muscle Invasive Bladder Cancer Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of Non Muscle Invasive Bladder Cancer Pipeline products with detailed clinical profiles, key cross -competition, launch date along with product development activities.. Non Muscle Invasive Bladder Cancer Pipeline. The high-grade NMIBC pipeline possesses potential drugs in mid and late stage ...
Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).: The study was initiated as an in vitro appr
TY - JOUR. T1 - Metastatic bladder cancer. T2 - Advances in treatment. AU - Stadler, W. M.. AU - Kuzel, T. M.. AU - Raghavan, D.. AU - Levine, E.. AU - Vogelzang, N. J.. AU - Roth, B.. AU - Dorr, F. A.. N1 - Funding Information: Acknowledgements---Studies were supported by research grants from Eli Lilly and Company.. PY - 1997/1. Y1 - 1997/1. N2 - At present, a combination of cisplatin, methotrexate, vinblastine and doxorubicin is the most widely used chemotherapy for metastatic bladder cancer. However, long-term follow up shows that this combination may have little effect on survival. In addition, this regimen is toxic. New agents are needed which combine efficacy with good safety profiles. Agents which have been investigated include gallium nitrate, interferon-α and paclitaxel both as single agents and in combination with established cytotoxic drugs. A number of studies have been conducted in bladder cancer with the novel nucleoside analogue, gemcitabine. Response rates of up to 33% have been ...
Clinical trial for Urothelial Carcinoma Bladder | bladder cancer | bladder disorder | transitional cell carcinoma of bladder | Urothelial Cancer | carcinoma of the bladder | Bladder Carcinoma | bladder tumor | urinary tract neoplasm | Urologic Cancer | Transitional Cell Carcinoma of the Bladder | Bladder Disorders , Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer
TY - JOUR. T1 - ICUD-EAU international consultation on bladder cancer 2012. T2 - Non-muscle-invasive urothelial carcinoma of the bladder. AU - Burger, Maximilian. AU - Oosterlinck, Willem. AU - Konety, Badrinath. AU - Chang, Sam. AU - Gudjonsson, Sigurdur. AU - Pruthi, Raj. AU - Soloway, Mark. AU - Solsona, Eduardo. AU - Sved, Paul. AU - Babjuk, Marko. AU - Brausi, Maurizio A.. AU - Cheng, Christopher. AU - Comperat, Eva. AU - Dinney, Colin. AU - Otto, Wolfgang. AU - Shah, Jay. AU - Thürof, Joachim. AU - Witjes, J. Alfred. PY - 2013/1. Y1 - 2013/1. N2 - Context: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. Objective: To critically review the recent data on the management of NMIBC to arrive at a general consensus. Evidence acquisition: A detailed Medline analysis was performed for original articles ...
TY - JOUR. T1 - Commentary on Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy.. AU - Thomas, D. E.. AU - Kaimakliotis, H. Z.. AU - Rice, K. R.. AU - Pereira, J. A.. AU - Johnston, P.. AU - Moore, M. L.. AU - Reed, A.. AU - Cregar, D. M.. AU - Franklin, C.. AU - Loman, R. L.. AU - Koch, M. O.. AU - Bihrle, R.. AU - Foster, R. S.. AU - Masterson, T. A.. AU - Gardner, T. A.. AU - Sundaram, C. P.. AU - Powell, C. R.. AU - Beck, S. D.W.. AU - Grignon, D. J.. AU - Cheng, L.. AU - Albany, C.. AU - Hahn, N. M.. PY - 2018/7. Y1 - 2018/7. N2 - Background: Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and clinical outcomes. Materials and ...
Treatment depends on the grade and extent of invasion of the bladder cancer. In most cases, an urgent transurethral resection of bladder tumour (TURBT) is carried out, and intravesical chemotherapy to reduce the risk of recurrence.. ​. Low grade, non-muscle invasive bladder cancer (Ta). TURBT + intravesical mitomycin C at the same time. Follow-up cystoscopy 3 months and then 12 months and discharge if no recurrence. If intermediate risk, follow-up cystoscopy at 3, 9, 18 months then yearly. If recurring ,12 months, give course of 6 doses intravesical mitomycin C. ​. High grade, non-muscle invasive bladder cancer (T1). TURBT. Either intravesical BCG immunotherapy or radical cystectomy. Cystectomy if poor response to ,2 sets BCG. Follow-up cystoscopy every 3 months for 2 years, then every 6 months for 2 years, then yearly. ​. Muscle invasive bladder cancer (T2-T4). Neoadjuvant chemotherapy. Radical cystectomy or radiotherapy. Follow-up: yearly imaging and monitoring of kidney function, ...
TY - JOUR. T1 - Antigen common to several species, recognized by a rat monoclonal antibody raised against syngeneic rat bladder tumor. AU - Eto, Hiroshi. AU - Saya, Hideyuki. AU - Nakata, Motomi. AU - Mizoguchi, Akira. AU - Kamidono, Sadao. PY - 1989/9/15. Y1 - 1989/9/15. N2 - A rat monoclonal antibody (MAb) termed RS‐11 (Ig M) was obtained by syngeneic immunization with rat bladder tumor cells induced by N‐butyl, N‐hydroxybutylnitrosamine (BBN). immunocytochemical analysis showed that RS‐11 is also reactive with mouse, dog and human bladder tumor‐cell lines and some other human tumor‐cell lines but not myeloma or leukemia cells. Immunohistochemical examination of paraffin‐embedded tissues has shown that RS‐11 is reactive with mouse, rat, dog and human bladder tumors (5/5, 5/5, 1/1, 31/ 49) and some other tumors, but not with normal human uro‐thelium or normal rat tissues. The antigen is expressed on the majority of low‐grade or well‐differentiated tumors, but less on ...
Bladder cancer is the fifth most common cancer in the United States with an estimated 71,000 new cases and approximately 14,000 deaths in 2009. Bladder cancer is also the costliest to treat per patient of all cancers, with annual direct medical expenditures in excess of $3.7 billion in the United States. This is largely because approximately 70% of all new cases of bladder cancer present as non-muscle invasive bladder cancer (NMIBC), which tends to recur, requiring repeated interventions and long-term follow-up.. NMIBC tumors are usually treated by surgical resection and intravesical chemotherapy and immunotherapy. Immunotherapy usually consists of intravesical administration of Bacillus Calmette-Guerin (BCG). Recent studies suggest that BCG is superior in terms of efficacy and decreasing disease recurrence compared to other therapies. Although the mechanism of action for BCG therapy leading to clinical efficacy is unclear, macrophages, T lymphocytes and natural killer (NK) cells are implicated ...
Gene expression profiling of bladder tumor cell lines and human bladder cancers. Isogenic T24T cells, bladder carcinoma-derived cell lines, primary human bladder carcinomas, and normal bladder tissues were profiled on HG-U133A GeneChip arrays (Affymetrix, Santa Clara, CA). For the previously described isogenic T24T cell pair containing vector or RhoGDI2 constructs ( 4), duplicate RNA samples were generated from independent cell cultures; RNA from the 41 human bladder cancer cell lines [acquired from American Type Culture Collection (Manassas, VA) or from Dr. Monica Liebert (M.D. Anderson Cancer Center, Houston, TX)] was generated from a single log-phase culture. Following approval of the University of Virginia Human Investigation Committee, 23 primary bladder cancer samples of varying pathologic stages and five samples of normal urothelium were obtained and evaluated by a genitourinary pathologist (H.F.F.). For the malignant samples, only areas containing ,80% cancer cells were processed for RNA ...
PURPOSE: Despite over 70,000 new cases of bladder cancer in the United States annually, patients with advanced disease have a poor prognosis due to limited treatment modalities. We evaluate the role of Aurora A, identified as an upregulated candidate molecule in bladder cancer, in regulating bladder tumor growth. EXPERIMENTAL DESIGN: Gene expression in human bladder cancer samples was evaluated using RNA microarray and reverse-transcriptase PCR. The specific Aurora kinase A inhibitor MLN8237 (Millennium) was used to determine effects on bladder cancer cell growth using in vitro and in vivo models using malignant T24 and UM-UC-3 and papilloma-derived RT4 bladder cells. RESULTS: Urothelial carcinoma upregulates a set of 13 mitotic spindle associated transcripts, as compared to normal urothelium, including MAD2L1 (7.6-fold), BUB1B (8.8-fold), Aurora kinases A (5.6-fold) and Aurora kinase B (6.2-fold). Application of MLN8237 (10nM-1µM) to the human bladder tumor cell lines T24 and UM-UC-3 induced dose
Clinical trial for Renal Cell Carcinoma | urinary tract cancer | Bladder Urothelial Carcinoma | Transitional Cell Carcinoma of the Bladder | Metastatic Kidney Carcinoma | clear cell renal cell carcinoma | Malignant Adenoma | Stage IV Renal Cell Cancer AJCC v8 | Adenocarcinoma | transitional cell carcinoma of bladder | Malignant neoplasm of kidney | Renal Cancer | Urologic Cancer | Renal Cell Cancer | Malignant Neoplasms of Urinary Tract | Kidney Cancer | urinary tract neoplasm , Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
In the United States, urothelial carcinoma (UC) of the bladder is the fourth most common malignancy in men and ninth most common in women with 72,570 new cases and 15,210 deaths expected in 2013. Bladder cancer can be divided into low-grade and high-grade tumors. While patients with low-grade tumors uniformly have a good prognosis, those with high-grade tumors clinical outcome is much worse and much more varied (so called heterogeneous). To better understand the heterogeneity within high-grade bladder cancer we examined the expression patterns of genes within a large group of high-grade, muscle-invasive bladder tumors and found that there are two distinct classes of bladder tumors that can be distinguished by their gene expression patterns but not by other means such as histology. Because of their similarity to several of the expression subtypes of breast cancer we have named the basal and luminal and developed a gene expression classifier consisting of 47 genes (BASE47) that can accurately ...
Pathology of Bladder Cancers, stages of bladder cancer, non-muscle invasive bladder cancer (NMIBC), personalized therapy for NMIBC, expected side effects of TURBT, costs involved for the management of bladder cancer.
Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial.
Approximately 70 percent of new urothelial (formerly called transitional cell) bladder cancer cases are classified as non-muscle invasive. Non-muscle invasive bladder cancer includes Ta, T1 (submucosal invasive) tumors, and Tis (carcinoma in situ [CI
Horvath, A, Simpson, GR, Coffin, RS, Mostafid, H and Pandha, H (2009) NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER: COMBINATION OF A FUSOGENIC GLYCOPROTEIN, PRO-DRUG ACTIVATION AND ONCOLYTIC HERPES SIMPLEX VIRUS ...
Urothelial bladder cancer is a highly heterogeneous disease. Cancer cell lines are useful tools for its study. This is a comprehensive genomic characterization of 40 urothelial bladder carcinoma (UBC) cell lines including information on origin, mutation status of genes implicated in bladder cancer (FGFR3, PIK3CA, TP53, and RAS), copy number alterations assessed using high density SNP arrays, uniparental disomy (UPD) events, and gene expression. Based on gene mutation patterns and genomic changes we identify lines representative of the FGFR3-driven tumor pathway and of the TP53/RB tumor suppressor-driven pathway. High-density array copy number analysis identified significant focal gains (1q32, 5p13.1-12, 7q11, and 7q33) and losses (i.e. 6p22.1) in regions altered in tumors but not previously described as affected in bladder cell lines. We also identify new evidence for frequent regions of UPD, often coinciding with regions reported to be lost in tumors. Previously undescribed chromosome X losses found in
Purpose To monitor the quality of bladder cancer care, the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997. During 2015, in order to study trends in incidence, effects of treatment and survival of men and women with bladder cancer, we linked the SNRUBC to other national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe). Participants The SNRUBC is a nationwide register with detailed information on 97% of bladder cancer cases in Sweden as compared with the Swedish Cancer Register. Participants in the SNRUBC have registered data on tumour characteristics at diagnosis, and for 98% of these treatment data have been captured. From 2009, the SNRUBC holds data on 88% of eligible participants for follow-up 5 years after diagnosis of non-muscle invasive bladder cancer, and from 2011, data on surgery details and complications for 85% of participants treated with radical cystectomy. The BladderBaSe includes all data in ...
TY - JOUR. T1 - BCG Immunotherapy Against Non-Muscle Invasive Bladder Cancer. T2 - Recent Results, Current Studies and Future Perspectives. AU - Takeuchi, Ario. AU - Shiota, Masaki. AU - Tatsugami, Katsunori. AU - Yokomizo, Akira. AU - Eto, Masatoshi. PY - 2016/1/1. Y1 - 2016/1/1. UR - http://www.scopus.com/inward/record.url?scp=84979097020&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84979097020&partnerID=8YFLogxK. M3 - Review article. C2 - 27333654. AN - SCOPUS:84979097020. VL - 107. SP - 8. EP - 11. JO - Fukuoka Acta Medica. JF - Fukuoka Acta Medica. SN - 0016-254X. IS - 1. ER - ...
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isnt fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive (NMI) bladder cancer eventually become the more dangerous, muscle-invasive (MI) form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?. A University of Colorado Cancer Center study published today in the journal Stem Cells shows its the latter: the progenitor cells that create MI bladder cancer are different than the progenitor cells that create NMI bladder cancer. Though these two cancers grow at the same site, they are different diseases.. This work provides an important new perspective on how we look at bladder cancer biology, says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center and the studys senior author.. The group including first author Garrett Dancik, PhD, ...
Maurice MJ, Vricella GJ, MacLennan G, Buehner P, Ponsky LE. Endoscopic snare resection of bladder tumors: evaluation of an alternative technique for bladder tumor resection. Journal of endourology. 2012;26:614-7. Bai Y, Liu L, Yuan H, et al. Safety and efficacy of transurethral laser therapy for bladder cancer: a systematic review and meta-analysis. World journal of surgical oncology. 2014;12:301. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. European urology. 2004;46:170-6. DUTTA SC, SMITH JA, SHAPPELL SB, COFFEY CS, CHANG SS, COOKSON MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. The Journal of urology. 2001;166:490-3. Suer E, Hamidi N, Gokce MI, et al. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. World journal of urology. 2016;34:847-51. Chen J, ...
This study aimed to investigate the effects of juglone on the human bladder carcinoma cell lines TCC-SUB and RT-4 in monolayer and spheroid cultures. Cells were treated with juglone at 24,48, and 72 h of incubation. The activity of caspase-3 was detected in vitro using a caspase-3 colorimetric assay kit according to the manufacturers instructions. The bromodeoxyuridine (BrdU) labeling index was used to determine the cells of the synthesis phase. The terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay was used to determine the death of cells in both the monolayer and spheroid cultures. The control group had a large S-phase fraction and many of the TCC-SUB and RT-4 cells nuclei were observed to be positive for BrdU. The dead cell count was higher in the TCC-SUB and RT-4 cell lines with juglone applied than in the controls. We conclude that juglone significantly inhibits the proliferation and induces the apoptosis of TCC-SUB and RT-4 cells in vitro. ...
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 combined with gemcitabine for patients who have BCG failure (defined as refractory, relapsing or intolerant), non-muscle invasive bladder cancer and refuse or are not medically fit to undergo a radical cystectomy recommended by the participating urologist as the standard next therapy per urologic guidelines. The purpose of this study is to confirm the safety and tolerability of a well-tolerated dose level of ALT-801, to determine the Recommended Dose level (RD) and characterize the immunogenicity of ALT-801 combined with gemcitabine in treated patients. The anti-tumor responses will also be assessed ...
TY - JOUR. T1 - Autophagy and urothelial carcinoma of the bladder. T2 - A review. AU - Chandrasekar, Thenappan. AU - Evans, Christopher P. PY - 2016. Y1 - 2016. N2 - The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little change in bladder cancer mortality in the past few decades. The mortality is mainly driven by muscle invasive bladder cancer, but the cancer burden remains high even in nonmuscle invasive bladder cancer due to high recurrence rates and risk of progression. While apoptosis deregulation has long been an established pathway for cancer progression, nonapoptotic pathways have gained prominence of late. Recent research in the role of autophagy in other malignancies, including its role in treatment resistance, has led to greater interest in the role of autophagy in bladder cancer. Herein, we summarize the literature regarding the ...
S100 calcium binding protein A8 (S100A8) has been implicated as a prognostic indicator in several types of cancer. However, previous studies are limited in their ability to predict the clinical behavior of the cancer. Here, we sought to identify a molecular signature based on S100A8 expression and to assess its usefulness as a prognostic indicator of disease progression in non-muscle invasive bladder cancer (NMIBC). We used 103 primary NMIBC specimens for microarray gene expression profiling. The median follow-up period for all patients was 57.6 months (range: 3.2 to 137.0 months). Various statistical methods, including the leave-one-out cross validation method, were applied to identify a gene expression signature able to predict the likelihood of progression. The prognostic value of the gene expression signature was validated in an independent cohort (n = 302). Kaplan-Meier estimates revealed significant differences in disease progression associated with the expression signature of S100A8-correlated
Muscle invasive bladder cancer (MIBC) is a cancer that spreads into the detrusor muscle of the bladder. The detrusor muscle is the thick muscle deep in the bladder wall. This cancer is more likely to spread to other parts of the body. About 1 out of 4 people who get bladder cancer in the United States have the muscle invasive kind.
Fingerprint Dive into the research topics of DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling. Together they form a unique fingerprint. ...
The Food and Drug Administration approved Keytruda for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer.|br /|  
The human bladder cancer cell lines, UMUC3 and HT1376, which were used in this study, were purchased from DS Pharma Biomedical (Osaka, Japan). UMUC3 cells were maintained in minimum essential medium (MEM) supplemented with MEM non-essential amino acids (NEAA) and sodium pyruvate (Gibco, St. Louis, MO, USA). HT1376 cells were maintained in RPMI-1640 medium (Wako, Osaka, Japan). Both media were supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, USA). The cells were incubated in a humidified incubator at 37°C in an atmosphere of 5% CO2 and 95% air. Each gemcitabine-resistant cell line (GR) was obtained from the parental UMUC3 or HT1376 cells.. The UMUC3 and HT1376 cells were grown in cell culture media containing gemcitabine (Wako), starting with a concentration of 10-2 µM. The cells were then passaged through stepwise increasing concentrations of gemcitabine up to a concentration of 50 µM. The cells were repeatedly passaged at each gemcitabine concentration in the stepwise ...
DiseaseFix brings interesting disease graphics, videos, pictures, photos, and images on Bladder Neoplasm. Watch graphics along with explanatory content at one place for Bladder Neoplasm. Causes, Symptoms, Diagnosis, Treatment.
Few studies have demonstrated gene/environment interactions in cancer research. Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (P-interaction ,= .001), rs11892031 (UGT1A, P-interaction = .01), and rs798766 (TMEM129-TACC3-FGFR3, P-interaction = .03). There was limited evidence for multiplicative interactions. When we examined detailed data on a prevalent occupational exposure associated with increased bladder cancer risk, straight metalworking fluids, we also observed statistically significant additive interaction for rs798766 (TMEM129-TACC3-FGFR3, P-interaction = .02), with the interaction more apparent in patients with tumors positive for FGFR3 expression. All statistical tests were two-sided. The interaction ...
Hi I am new to this forum and wondered if I could get some support from this forum. My mother has recently been diagnosed with muscle invasive bladder cancer in...
In this work we have used Fourier transform infrared (FTIR) / vibrational absorption (VA) spectroscopy to study two cancer cell lines: the Henrietta Lacks (HeLa) human cervix carcinoma and 5637 human bladder carcinoma cell lines. Our goal is to experimentally investigate biochemical changes and differences in these cells lines utilizing FTIR spectroscopy. We have used the chemometrical and statistical method principal component analysis (PCA) to investigate the spectral differences. We have been able to identify certain bands in the spectra which are so-called biomarkers for two types of cell lines, three groups for the 5637 human bladder carcinoma cell line (5637A, 5637B and 5637C), and another one for the HeLa human cervix carcinoma cell line. The vibrational modes can be assigned to specific bands involving characteristic motions of the protein backbone. This work shows that infrared vibrational absorption (VA) spectroscopy can be used as a useful tool in medical diagnostics that provides in ...
TY - JOUR. T1 - Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. AU - Chaturvedi, Vijaya. AU - Li, Li. AU - Hodges, Sherie. AU - Johnston, Dennis. AU - Ro, Jae Y.. AU - Logothetis, Christopher. AU - Von Eschenbach, Andrew C.. AU - Batsakis, John G.. AU - Czerniak, Bogdan. PY - 1997. Y1 - 1997. N2 - Multistep alterations of chromosome 17 in the progression of human urinary bladder neoplasia were studied by superimposed histologic and genetic mapping. The p53 gene was included in the analysis as a model tumor suppressor gene that is frequently involved in urothelial carcinogenesis. The strategy provided a systematic approach to the study of multistep genomic alterations that occur as neoplasia progresses from precursor intraurothelial conditions to invasive cancer. This was accomplished by sampling the entire mucosa of the organ and displaying microscopically identified invasive cancer and precursor conditions in the form of a histologic ...
Publications, guidelines and educational videos on Non Muscle Invasive Bladder Cancer (NMIBC). Open access. Content provided by Elsevier.
There are limited established therapies for bladder cancer, which can be lethal if it reaches advanced stages and invades surrounding muscle tissue. Segovia, San José-Enériz, Munera-Maravilla, and colleagues found that expression of the histone methyltransferase G9a, suggested in prior studies to be a bladder cancer oncoprotein, was higher in human non-muscle-invasive bladder cancer tumors than in adjacent healthy tissue, and higher levels of the G9a mRNA and protein were correlated with increased chance of bladder cancer recurrence. CM-272, a G9a/DNMT inhibitor, inhibited cell proliferation in some bladder cancer cell lines, and cell lines resistant to CM-272 had mutations in PIK3CA. Because G9a and EZH2 coregulate H3K27me3 and activating mutations in PIK3CA reduce EZH2 and H3K27me3 in bladder cancer, CM-272 resistance may be related to EZH2 activity; supporting this, PIK3CA-mutant bladder cancer cells had decreased EZH2 levels, and PIK3CA-mutant bladder cancer cells exhibited EZH2 ...
METHODS: Human bladder cancer BIU-87 cell lines were cultured in vitro. Different concentrations of gambogic acids were added to the logarithmic growth phase in the human bladder cancer BIU-87 cells for further cultivation. Caspase-3 protein expression in tumor tissue was detected by immunohistochemical S-P method. The gambogic acid-induced apoptosis in human bladder cancer cells and cell cycle changes were detected and analyzed using flow cytometry ...
The wall of the bladder is lined with several layers of cells called transitional cells. Cancer arising from these cells makes up more than 90% of all bladder cancers and these are referred to as transitional cell carcinomas. Because transitional cell carcinomas are the most common type of bladder cancer, the information in this section only addresses treatment of transitional cell cancer of the bladder. Bladder cancer occurs predominantly in elderly men and less frequently in women and younger men. Many bladder cancers are thought to be caused by exposure to cancer-causing agents that pass through the urine and come into contact with the bladder lining. The most important risk factor for bladder cancer is smoking, which increases risk by at least four-fold.[1]. The most common sign of bladder cancer is hematuria or blood in the urine, which will turn the urine rust or red in color.[2] Other signs of bladder cancer may include pain during urination and frequent urination. Most patients with ...
Non-Muscle Invasive Bladder Cancer (NMIBC) is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.. The high-grade NMIBC pipeline possesses potential drugs in mid and late stage developments to be launched in the near future. The major key players include Viventia Bio/Sesen Bio (Vicinium), FKD Therapies Oy/Ferring Pharmaceuticals (Adstiladrin), CG Oncology (CG0070), ImmunityBio/Altor Biosciences (N-803 (ALT-803)), Theralase (TLD-1433), Merck (Keytruda) and others that hold the potential to create a significant positive shift in NMIBC in the market size.. Keytruda is developed by Merck and marketed in the United States which is a humanized monoclonal antibody that binds to the programmed cell death- 1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the ...
We have analyzed the methylation pattern of RARβ, DAPK, E-cadherin, p15, p16, MGMT, and GSTP1 in bladder TCC of different stages and grades. In our study, all of our samples have at least one gene methylated, and more than three genes that were methylated accounted for 20% of our cases. Thus, the epigenetic event of gene methylation was frequent in bladder cancer. However, this phenomenon did not appear to be correlated with disease grade or stage.. Reports on the methylation of various genes have been described in primary bladder cancer (12, 13, 14, 15, 16, 17, 18, 19) . Among these reports, methylation of p16 was most commonly investigated. The frequency of p16 methylation in bladder TCC ranged from 9-67% (13, 14, 15, 16, 17 , 19) . Our study represented the largest series and demonstrated p16 methylation of 26.5%. Tumor suppressor gene p16 specifically inactivates cyclin-dependent kinase 4 and cyclin-dependent kinase 6, which interact with cyclin D1 and stimulate the progression of the cell ...
In the present study we demonstrated for the first time that, Pim-1 was increased in human bladder cancer epithelium as compared with that in normal bladder tissue. When the tumors were stratified by Non-invasive and invasive, a statistically significant increase of Pim-1 expression was found in the subgroup of invasive tumor when compared with that in the Non-invasive tumor. Pim-1 was also detected in all human bladder cancer cell lines tested in our study. Knockdown Pim-1 led to decreased phosphorylation of Bad and reduced expression of Bcl-2. Furthermore, downregulation of Pim-1 inhibited the bladder cancer cells growth and sensitized them to chemotherapy in vitro. Further evaluation of the prognostic significance of Pim-1 in a larger cohort with sufficient follow-up times will allow better understand of the clinical significance of Pim-1.. Overexpression of the Pim-1 protein has been reported in hematolymphoid malignancies and solid cancers [4, 5]. Pim-1 has been asserted to promote ...
p,,b,BACKGROUND: ,/b,In the past decade, adjuvant chemotherapy (AC) after radical cystectomy (RC) was preferred worldwide for patients with muscle-invasive urothelial bladder cancer. In this study we aimed to determine the outcome of patients who received AC and evaluated prognostic factors associated with survival.,/p,,p,,b,PATIENTS AND METHODS: ,/b,We retrospectively analyzed 226 consecutive patients treated in 6 academic hospitals between 2000 and 2009. Multivariate Cox proportional hazards regression adjusted for center to estimate adjusted hazard ratios (HRs) with 95% confidence intervals were used.,/p,,p,,b,RESULTS: ,/b,The median age was 62.4 (range, 35-82) years. Patients had pT3/pT4 and/or pN+ in 180 (79.6%) and 168 patients (74.3%), respectively. Median lymph node (LN) density was 25% (range, 3.1-100). Median time between RC and AC was 61.5 (range, 18-162) days. Gemcitabine with cisplatin, gemcitabine with carboplatin, and MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) ...
Treatment of Non Muscle Invasive Bladder Tumor Related to the Problem of Bacillus Calmette-Guerin Availability. Consensus of a Spanish Experts ...
The hexylester of 5-aminolevulinic acid (HAL) is a very efficient precursor of the photosensitizer protoporphyrin IX (PpIX) for photodynamic therapy (PDT). Our previous study, performed in rat orthotopic bladder tumors, indicated an opposite effect of HAL/PpIX-PDT according to HAL concentration. The present study investigated possible reasons for this differential effect considering the impact of extracted amounts of PpIX in normal and tumor bearing bladders along with PpIX distribution in distinctive histopathological layers. High performance liquid chromatography (HPLC) analysis of tumor and normal bladder tissues after 8 mM and 16 mM HAL instillation showed that PpIX was the main porphyrin species. The PpIX production in tumor bladders instilled with 8 mM HAL was significantly higher than after 16 mM HAL. Fluorescence confocal microscopy demonstrated a punctuate bright fluorescence pattern in tumor zones of bladders instilled with 8 mM HAL, whereas a more diffuse cytoplasmatic fluorescence
View Poster. INTRODUCTION. There has been increasing awareness of the importance of three-dimensional culture of cancer cells. Tumor cells growing as multicellular spheroids (organoids) are believed to more closely mimic solid tumors in situ. Meanwhile, Wnt/β-catenin pathway was reported to be upregulated in human bladder cancer specimens. However, no clear evidence has been reported that the pathway is directly involved in proliferation of bladder cancer cells. In this study, we assessed the involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells using organoid culture.. METHODS. Organoids from bladder cancer cell lines RT4 (luminal phenotype) and 5637 (basal phenotype) were generated by an aggregation method. A partial-digestion method was applied to prepare organoids directly from patient bladder cancer specimens. Wnt/β-catenin pathway was activated by using a small molecule CHIR99021 (GSK3 inhibitor, Wnt activator) and inhibited by siRNA against β-catenin. ...
Fingerprint Dive into the research topics of Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: Comparative study of immunohistochemistry and fluorescent in situ hybridization. Together they form a unique fingerprint. ...
TY - JOUR. T1 - Cantharidin-induced cytotoxicity and cyclooxygenase 2 expression in human bladder carcinoma cell line. AU - Huan, Steven Kuan Hua. AU - Lee, Hao Hsien. AU - Liu, Der Zen. AU - Wu, Chien Chih. AU - Wang, Ching Chiung. PY - 2006/6/1. Y1 - 2006/6/1. N2 - Mylabris is used in clinical therapy, but is always accompanied by cystitis. The toxic effects of mylabris on bladder are attributed to its active principle: cantharidin. In the present study, we explored how cantharidin induces cytotoxicity in the bladder. Human bladder carcinoma cell line T 24 cells were used as target cells, and human colon carcinoma HT 29 cells as native cells. Cantharidin exhibited acute cytotoxicity in the T 24 cells, and IC50 was 21.8, 11.2 and 4.6 μM after treatment for 6, 24 and 48 h, respectively. The cytotoxicity of cantharidin was not significantly enhanced when T 24 cells were treated for a longer time. Moreover, PARP proteins and pro-caspase 3, Bcl-2 were significantly inhibited after cantharidin ...
TY - JOUR. T1 - Granulocyte-colony stimulating factor receptor expression on human transitional cell carcinoma of the bladder. AU - Tachibana, Masaaki. AU - Miyakawa, Ayako. AU - Uchida, Atsushi. AU - Sumitomo, Makoto. AU - Nakamura, Kayoko. AU - Murai, Masaru. PY - 1997/12/1. Y1 - 1997/12/1. N2 - Receptors for granulocyte-colony stimulating factor (G-CSFR) have been confirmed on the cell surfaces of several nonhaematopoietic cell types, including bladder cancer cells. This observation has naturally led to the hypothesis that the expression of G-CSFR on these cells may enhance their growth by G-CSF. In this study, the expression of G-CSFR was determined both in established human bladder cancer cell lines and primary bladder cancers. We studied five different human bladder cancer cell lines (KU-1, KU-7, T-24, NBT-2 and KK) and 26 newly diagnosed bladder tumors. G-CSFR mRNA expressions on cultured cell lines were determined using the reverse transcriptase-polymerase chain reaction (RT-PCR) method. ...
U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT03113266) titled Safety and Efficacy of JS001 for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma on April 6. Brief Summary: This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic bladder urothelial carcinoma who have failed in routine systemic treatment. Study Start Date: Study Type: Interventional Condition: Bladder Urothelial Carcinoma Intervention: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically. Other Name: JS001 Recruitment Status: Recruiting Sponsor: Shanghai Junshi ...
TY - JOUR. T1 - The effect of mitomycin C on superficial bladder cancer. AU - Soloway, M. S.. AU - Murphy, W. M.. AU - DeFuria, M. D.. AU - Crooke, S.. AU - Finebaum, P.. PY - 1981/1/1. Y1 - 1981/1/1. N2 - A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.. AB - A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer ...
Fresh, superficial transitional cell carcinomas (TCCs) of low-grade atypia (3 grade I, Ta; 6 grade II, Ta), as well as primary cultures derived from them were labeled with [35S]methionine for 16 h, between 2 and 6 days after inoculation. Whole protein extracts were subjected to IEF (isoelectric focu …
TY - JOUR. T1 - Analysis of matrix metalloproteinase expression in the recurrence of superficial low grade urothelial bladder cancer. AU - Choi, Young Deuk. AU - Ahn, Hyun Soo. AU - Cho, Nam Hoon. AU - Lee, Mee Kyung. AU - Kang, Sook Hee. AU - Yang, Won Jae. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2005/4. Y1 - 2005/4. N2 - Purpose: Superficial bladder transitional cell carcinomas (TCCa) have high recurrence rates following endoscopic resection. Most of the parameters used for the prediction of a recurrence are associated with high grade TCCa. However, there are few valid parameters for prediction of the recurrence of low grade TCCa. We aimed to elucidate the prime factor of a recurrence of superficial low grade bladder TCCa. Materials and methods: Thirty cases of superficial low grade bladder TCCa were analyzed, 15 of which were recurred cases. Fresh frozen tumor and normal tissues were used for the analysis. Real-time reverse transcriptase polymerase chain ...
Request a copy of Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer., a 21st Century Oncology physician publication.
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure Academic Article ...
Prior studies well established that urothelial carcinoma harbors remarkable propensity for divergent differentiation [12-14]. Squamous differentiation has been suggested to be the most common histological variation in bladder urothelial carcinoma and it may present basaloid or clear cell features [15]. However, mechanisms of squamous differentiation in urothelial carcinoma is not very clear. In 1925, Wolbach and Howe found that long time vitamin A deficiency treatment could lead to bladder squamous differentiation in rats [16]. More recently, several findings together with previous studies on the development of squamous differentiation under condition of retinoid deficiency, strongly recommend that retinoid signaling pathways and related networks are significant in the development of squamous lesions in the urinary bladder [17-20]. Maraver et al. showed that downregulation of NOTCH signaling contributed to occurrence of aggression in squamous lesions [21, 22]. Some transcriptional regulators ...
TY - JOUR. T1 - Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. T2 - Clinical Genitourinary Cancer. AU - Rosiello, G.. AU - Knipper, S.. AU - Palumbo, C.. AU - Pecoraro, A.. AU - Luzzago, S.. AU - Deuker, M.. AU - Tian, Z.. AU - Gandaglia, G.. AU - Gallina, A.. AU - Montorsi, F.. AU - Shariat, S.F.. AU - Saad, F.. AU - Briganti, A.. AU - Karakiewicz, P.I.. N1 - Cited By :1 Export Date: 11 March 2021 Correspondence Address: Rosiello, G.; Department of Urology and Division of Experimental Oncology, Via Olgettina, Italy; email: [email protected] PY - 2020. Y1 - 2020. N2 - Background: Our objective was to test whether the rates of perioperative chemotherapy (CHT) administration in patients with urothelial bladder cancer (UCUB) with prostatic stromal invasion (pT4a) changed over time. Moreover, we tested the effect of CHT on overall mortality (OM), as well as on cancer-specific ...
Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder Cancer Adenosine triphosphate;chemotherapy response assay;superficial bladder cancer; Objective: To investigate correlations between adenosine triphosphate chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-based chemotherapy for drug selection in patients receiving intravesical chemotherapy to prevent recurrence of superficial bladder cancer after surgery. Methods: The chemosensitivities of 12 anticancer drugs were evaluated, including 5-Fu ADM, and EPI, using ATP-CRA and primary tumor cell culture in 54 patients. In addition, a further 58 patients were treated according to clinical experience. Differences in post-chemotherapeutical effects between drug sensitivity assay and experience groups were compared. Results: The evaluable rate of the test was 96.3%, the clinical effective rate was 80.8%, the sensitivity rate was 97.6% (41/42), the specificity was
TY - JOUR. T1 - The use of regenerative medicine in the management of invasive bladder cancer. AU - Hyndman, Matthew E.. AU - Kaye, Deborah. AU - Field, Nicholas C.. AU - Lawson, Keith A.. AU - Smith, Norm D.. AU - Steinberg, Gary D.. AU - Schoenberg, Mark P.. AU - Bivalacqua, Trinity J.. PY - 2012. Y1 - 2012. N2 - Muscle invasive and recurrent nonmuscle invasive bladder cancers have been traditionally treated with a radical cystectomy and urinary diversion. The urinary diversion is generally accomplished through the creation of an incontinent ileal conduit, continent catheterizable reservoir, or orthotopic neobladder utilizing small or large intestine. While radical extirpation of the bladder is often successful from an oncological perspective, there is a significant morbidity associated with enteric interposition within the genitourinary tract. Therefore, there is a great opportunity to decrease the morbidity of the surgical management of bladder cancer through utilization of novel ...
Is it time for urologists to begin to rethink the radical cystectomy and begin to explore trimodality therapy? Maybe - maybe not - it depends on who you ask. Lets go over a few things first, though, before we jump right in.. (TMT) Trimodality Therapy is not some radical new line of treatment. The Tri stands for three modalities of treatment: chemotherapy, radiotherapy, and surgery. And again, while nothing new, the treatments used in combination to fight bladder cancer are a course of treatment that allows the patient to keep their bladder rather than have it removed.. (RC) Radical Cystectomy is typically the removal of the entire bladder, lymph nodes in proximity to the bladder, part of the urethra, and any organ tissue in proximity that does or could have cancerous cells.. For women, it can - but not always - entail uterus, ovaries, fallopian tubes, and part of the vagina being removed.. For men, it can - but not always - entail prostate, seminal vesicles, part of the vas deferens being ...
TY - JOUR. T1 - Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma. T2 - A matched cohort analysis. AU - Wang, Jeffrey K.. AU - Boorjian, Stephen A.. AU - Cheville, John C.. AU - Kim, Simon P.. AU - Tarrell, Robert F.. AU - Thapa, Prabin. AU - Frank, Igor. PY - 2012/12/1. Y1 - 2012/12/1. N2 - Purpose: Micropapillary (MP) bladder cancer is a rare variant of urothelial carcinoma (UC) which has been associated with an aggressive natural history. We sought to report the outcomes of patients with MP bladder cancer treated with radical cystectomy (RC) and compare survival to patients with pure UC of the bladder. Methods: We identified 73 patients with MP bladder cancer and 748 patients with pure UC who underwent RC at our institution with median postoperative follow-up of 9.6 years. MP patients were stage-matched 1:2 to patients with pure UC. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Results: MP ...
Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education. ...
Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education. ...
PURPOSE: Salvage cystoprostatectomy has evolved as a safe and potentially curative treatment option for patients with radiation recurrent bladder cancer. Although orthotopic bladder replacement remains the preferred form of urinary diversion, there is minimal information about its role in salvage cystectomy series. We describe our limited experience in this regard. MATERIAL AND METHODS: We evaluated the operative characteristics and outcome of two patients with muscle invasive transitional cell carcinoma (TCC) of the urinary bladder after failed high-dose radiation therapy (mean 6,490 cGy). Both patients underwent salvage cystoprostatectomy with Studer-type ileal neobladder reconstruction. Existing literature on the topic is reviewed. RESULTS: Final histopathology showed pT3 N0 M0 TCC urinary bladder with no recent evidence of tumor recurrence. There was no mortality or major perioperative complication. Mean surgery time was 590 minutes, and mean blood loss was 1,600 mL, with 3.5 U of packed cell
A look at the following clinical trial: Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery.
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Noninvasive transitional cell carcinomas of the bladder can have two distinct morphologies suggesting they contain different genetic alterations. Papillary transitional cell carcinomas (Ta tumors) are often multifocal and only occasionally progress, whereas flat tumors (carcinomas in situ, CIS), frequently progress to invasive disease. We examined 216 bladder tumors of various stages and histopathologies for two genetic alterations previously described to be of importance in bladder tumorigenesis. Loss of heterozygosity of chromosome 9 was observed in 24 of 70 (34%) Ta tumors but was present in only 3 of 24 (12%) CIS and dysplasia lesions (P = 0.04). In contrast, only 1 of 36 (3%) Ta tumors contained a p53 gene mutation compared to 15 of 23 (65%) CIS and dysplasias (P , 0.001), a frequency comparable to that observed in muscle invasive tumors (25 of 49; 51%). The presence of p53 mutations in CIS and dysplasia could explain their propensities to progress since these mutations are known to ...
The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma Academic Article Article ...
TY - JOUR. T1 - Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. AU - Kluth, Luis A.. AU - Xylinas, Evanguelos. AU - Crivelli, Joseph J.. AU - Passoni, Niccolo. AU - Comploj, Evi. AU - Pycha, Armin. AU - Chrystal, James. AU - Sun, Maxine. AU - Karakiewicz, Pierre I.. AU - Gontero, Paolo. AU - Lotan, Yair. AU - Chun, Felix K H. AU - Fisch, Margit. AU - Scherr, Douglas S.. AU - Shariat, Shahrokh F.. PY - 2013/8. Y1 - 2013/8. N2 - Purpose: To our knowledge the impact of body mass index on oncologic outcomes in nonmuscle invasive bladder cancer has not been evaluated. We hypothesized that higher body mass index is associated with worse outcomes in patients with clinical primary T1 high grade urothelial carcinoma of the bladder. Materials and Methods: We retrospectively analyzed data from 892 patients with primary nonmuscle invasive bladder cancer from 7 centers. Patients were treated with transurethral resection of the bladder with or ...
Background This study aimed to judge the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or both drugs to untreated ones. high stage disease (T1) attained the amount of unbiased risk aspect for the incident of the recurrence. When sufferers were stratified based on the different treatment; sufferers treated with statins (Group B) provided an higher level of failing (56/91 sufferers; 61.5%) in comparison with Group A (42/98 sufferers; 42.9%), Group C (56/98; 57.1%) and (133/287 sufferers; 46.3%). This difference corresponds to a big change in recurrence failing free success (p?=?0.01). Conclusions Our outcomes claim that long-term treatment with aspirin in sufferers with NMIBC might are likely involved on reducing the chance of tumor recurrence. On the other hand, in our analysis data from statins and mixture treatment groups demonstrated increased recurrence prices. ...
Background The rationale for combining anticancer drugs has not been applied consistently to use of intravesical agents for treatment of superficial bladder cancer, for which immunotherapeutic BCG and chemotherapeutic mitomycin seem to be a potentially effective combination. We aimed to do a prospective, randomised comparison of BCG alone with that of sequential BCG and electromotive mitomycin in patients with stage pT1 bladder cancer. Methods After transurethral resection and multiple biopsies, 212 patients with stage pT1 bladder cancer were randomly assigned to: 81 mg BCG infused over 120 min once a week for 6 weeks (n=105); or to 81 mg BCG infused over 120 min once a week for 2 weeks, followed by 40 mg electromotive mitomycin (intravesical electric current 20 mA for 30 min) once a week as one cycle for three cycles (n=107). Complete responders underwent maintenance treatment: those assigned BCG alone had one infusion of 81 mg BCG once a month for 10 months, and those assigned BCG and ...
TY - JOUR. T1 - Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. AU - Shiota, Masaki. AU - Takeuchi, Ario. AU - Yokomizo, Akira. AU - Kashiwagi, Eiji. AU - Tatsugami, Katsunori. AU - Kuroiwa, Kentaro. AU - Naito, Seiji. PY - 2012/7. Y1 - 2012/7. N2 - Purpose: There are several reports of androgen receptor in bladder cancer cases but androgen receptor expression and the function of androgen/androgen receptor signaling in bladder cancer remain unclear. We investigated androgen receptor expression and the role of androgen/androgen receptor signaling in bladder cancer. Materials and Methods: We evaluated AR mRNA expression in bladder cancer tissue by quantitative real-time polymerase chain reaction. The role of androgen receptor in cell growth and drug sensitivity was also evaluated in vitro and in vivo in several bladder cancer cell lines. Results: AR mRNA expression inversely correlated with bladder cancer grade, stage and spread. Of several ...
Lutheran/basal cell adhesion molecule (Lu/BCAM) is a membrane bound glycoprotein. This study was performed to investigate the role and downstream signaling pathway of Lu/BCAM in human bladder tumorigenesis. Five human bladder cancer (E6, RT4, TSGH8301, TCCSUP and J82), one stable mouse fibroblast cell line (NIH-Lu) expressing Lu/BCAM transgene and sixty human uroepithelial carcinoma specimens were analyzed by real-time PCR, immunohistochemistry (IHC), immunofluorescence (IFA) staining, Western blotting and promoter luciferase assay for Lu/BCAM, respectively. The tumorigenicity of Lu/BCAM was demonstrated by focus formation, colony-forming ability, tumour formation, cell adhesion and migration. H-ras V12 was revealed to up-regulate Lu/BCAM at both transcriptional and translation levels. Lu/BCAM expression was detected on the membrane of primary human bladder cancer cells. Over-expression of Lu/BCAM in NIH-Lu stable cells increased focus
OBJECTIVES To assess the efficacy of nuclear matrix protein 22 (NMP-22) in the diagnosis of recurrent, superficial bladder cancer and whether it can predict for future recurrence. METHODS Patients with diagnosed and treated superficial transitional cell carcinoma urinary bladder (Stage Ta, T1, Tis, Nx, and M0) presenting for surveillance follow-up were prospectively enrolled in this study from February 2004 to August 2005. These patients underwent urine cytology, NMP-22 testing, and cystopanendoscopy on enrollment in the study. For the next year, these patients underwent cystopanendoscopy and cytology at 3-month intervals. The ability of NMP-22 to predict for recurrence was determined using the cystoscopy findings as the reference standard. RESULTS A total of 145 patients were included in the study. Of these, 56 had recurrence at enrollment. Of the 56 patients, 48 had positive NMP-22 findings and 22 had positive urine cytology findings. The sensitivity, specificity, positive predictive value, and
Bladder cancer treatment is dependent on the depth of invasion through the bladder wall. Superficial bladder cancers are treated by resection through the urethra, known as transurethral resection of bladder tumor (TURBT). Under general anesthesia, a scope is inserted into the urethra to navigate the anatomic tube through which the urine exits the body.For bladder cancer that invades into the muscle of the bladder wall, the gold standard therapy is surgical removal of the entire bladder (radical cystectomy), and dissection of a lymph node to detect whether cancer has spread beyond the bladder. In men, the prostate and seminal vesicles are also removed. Bladder replacement options are performed with the use of an intestinal segment and are classified as either: (1) incontinent or (2) continent.An incontinent diversion (ileal conduit) requires a bag to be placed over a stoma to capture urine that drains as it is produced.A continent diversion stores urine and comes in two types: (1) neobladder or (2)
http://www.statistik.at/web_de/statistik... ). The optimal management of geriatric patients with invasive bladder cancer will increasingly become an important issue. In younger patients with MIBC, RC remains the gold standard of therapy (33. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al.: Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21: 690-6.,1212. Skinner DG, Stein JP, Lieskovsky G, Skinner EC, Boyd SD, Figueroa A, et al.: 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol. 1998; 33(Suppl 4): 25-6.). However, geriatric patients have a higher number of relevant comorbidities resulting in an enhanced surgical risk. Prout et al. (1313. Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK: Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer. 2005; 104: 1638-47.) reported ...
MeSH-minor] Brachytherapy. Combined Modality Therapy. Controlled Clinical Trials as Topic. Cystectomy. Data Interpretation, Statistical. Dose Fractionation. Female. Humans. Kidney / pathology. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Kidney Neoplasms / radiotherapy. Kidney Neoplasms / surgery. Male. Meta-Analysis as Topic. Neoplasm Staging. Nephrectomy. Organ Preservation. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Ureter / pathology. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / mortality. Ureteral Neoplasms / pathology. Ureteral Neoplasms / radiotherapy. Urethra / pathology. Urethral Neoplasms / drug therapy. Urethral Neoplasms / mortality. Urethral Neoplasms / pathology. Urethral Neoplasms / radiotherapy. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / radiotherapy. Urinary Bladder Neoplasms / ...
Highlights: Black-Right-Pointing-Pointer The tumor suppressor gene PDCD4 is down-regulated in many tumorous entities. Black-Right-Pointing-Pointer We investigate the impact of PDCD4 and its regulating factor miR-21 in urothelial carcinoma. Black-Right-Pointing-Pointer We confirm PDCD4 as a tumor suppressor gene and it could be a diagnostic marker for this tumor. -- Abstract: Background: We investigated the role of the programmed cell death 4 (PDCD4) tumor suppressor gene in specimens of transitional cell carcinoma and of healthy individuals. Methods: PDCD4 immunohistochemical expression was investigated in 294 cases in histologically proven transitional cell carcinoma in different tumorous stages (28 controls, 122 non-muscle invasive urothelial carcinoma, stages Tis-T1, 119 invasive transitional cell carcinoma stages T2-T4 and 25 metastases). MiR-21 expression, an important PDCD4 regulator, was assessed with real-time PCR analysis and showed inverse correlation to tissue PDCD4 expression. ...
Spectrum of computed tomography findings in gall bladder carcinoma patients: a retrospective observational study from tertiary care oncology setup
Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide shortage. We review the literature examining the BCG shortage and propose solutions to cope with this problem.
Long-term results were analyzed in terms of tumor progression and survival in patients with superficial bladder cancer who were enrolled in the second intravesical chemoprophylactic study of the...
Abstract Bladder cancer is one of the most common malignancies and causes hundreds of thousands of deaths worldwide each year. Bladder cancer is strongly associated with exposure to environmental carcinogens. It is believed that DNA damage generated by environmental carcinogens and their metabolites causes development of bladder cancer. Nucleotide excision repair (NER) is the major DNA repair pathway for repairing bulk DNA damage generated by most environmental carcinogens, and XPC is a DNA damage recognition protein required for initiation of the NER process. Recent studies demonstrate reduced levels of XPC protein in tumors for a majority of bladder cancer patients. In this work we investigated the role of histone deacetylases (HDACs) in XPC gene silencing and bladder cancer development. The results of our HDAC inhibition study revealed that the treatment of HTB4 and HTB9 bladder cancer cells with the HDAC inhibitor valproic acid (VPA) caused an increase in transcription of the XPC gene in these cells
Cheapest Transurethral Resection Of Bladder Tumor TURBT price in Cuttack, India is $. Average Transurethral Resection Of Bladder Tumor TURBT cost $0, where prices can go as high as $. PlacidWay Medical Tourism provides cost comparison for Transurethral Resection Of Bladder Tumor TURBT, Urology Prices in Cuttack, India. Explore Transurethral Resection Of Bladder Tumor TURBT prices worldwide.
The urogenous-contact hypothesis proposes that the development of bladder cancer is associated with prolonged exposure to carcinogens in urine. To fully examine this hypothesis, this dissertation systematically addressed fluid intake, micturition habits, associated medical conditions, and medications in relation to risk of bladder cancer in the Los Angeles Bladder Cancer Case-Control Study.; Total fluid intake was not associated with risk of bladder cancer, but specific types of beverages had different influence on bladder cancer. Consumption of water and alcoholic beverages were associated with a reduced risk of bladder cancer, whereas consumption of coffee was associated with a slightly increased risk, especially among heavy drinkers. The alcohol-bladder cancer association was modified by genetic variations in glutathione S-transferases, and the coffee-bladder cancer association was modified by variations in N-acetyltransferase 2 and cytochrome P450 1A2.; This dissertation also examined the ...
Tobacco consumption has been implicated as the most relevant risk factor for the development of bladder cancer. Among various carcinogens identified in tobacco smoke, the polycyclic aromatic hydrocarbons (PAHs) are well characterized and their risk associations with bladder cancer are well studied [1-4]. In addition to these strong environmental risk factors, recent genome-wide association studies have identified several highly significant genetic factors with small effects [5, 6]. Some of these have been shown to modify the effects of smoking on risk of bladder cancer [7].. Most existing genetic association studies have focused on the independent effects of individual genes. That is, they have by design ignored the context of human ecology and the extensive variability in the human genome. As a result, much of the heritability of common human diseases such as bladder cancer remains unexplained. Multiple approaches have been proposed to account for this missing heritability including sequencing ...
OncologyPRO is the home of ESMOs educational & scientific resources, with exclusive content for ESMO members such as ESMOs Congresses webcasts,
New chemotherapeutic agents undergoing evaluation in prospective clinical trials include vinflunine, ixabepilone as well as others. 3. Immunotherapy for patients with metastatic or unresectable bladder cancer The role of immunotherapy has long been established in non-muscle-invasive bladder cancer. The localized inflammatory response to intravesical BCG appears to be the source of its anti-tumor activity. For advanced or metastatic urothelial carcinomas, there is now an established role for immune checkpoint inhibitors. Currently, 5 antibodies targeting the PD1/PD-L1 axis are FDA approved for this indication. The PD-1 inhibitor pembrolizumab is approved for the treatment of patients with advanced or metastatic urothelial carcinomas who have progressed on or following prior platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. This approval is based on improved overall survival (OS) with pembrolizumab compared to cytotoxic chemotherapy. ...
Polyps are commonly found in the colon, stomach, nose, ear, sinus(es), urinary bladder, and uterus. They may also occur ... Some polyps are tumors (neoplasms) and others are non-neoplastic, for example hyperplastic or dysplastic. The neoplastic ones ...
February 1999). "Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia ... which may be benign neoplasms) or else a malignant neoplasm (cancer). These neoplasms are also indicated, in the diagram below ... In bladder cancer, clones with loss of p16 were observed to have spread over the entire surface of the bladder.[64][65] ... "Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications". Int. J. ...
Histopathology of urothelial carcinoma of the urinary bladder. Histopathology of urothelial carcinoma of the urinary bladder. ... papillary neoplasm of low malignant potential [PNLMP], low grade, and high grade papillary carcinoma). Papillary transitional ... Punyavoravut V, Nelson SD (August 1999). "Diffuse bony metastasis from transitional cell carcinoma of urinary bladder: a case ... It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. It accounts for 95% of bladder ...
... and urinary bladder or gallbladder, biliary tract, pancreas, ampulla of Vater or uterine cervix. Immunohistochemistry may help ... in diagnosing Krukenberg tumors from primary ovarian neoplasms but needs to be applied with discretion. For example, tumors ...
Also decreased CK1δ mRNA expression levels have been observed in some cancer studies, like urinary bladder cancer, lung ... hematopoietic malignancies and lymphoid neoplasms. ... among them bladder cancer, brain cancer, breast cancer, ...
... papillary transitional cell carcinoma of the urinary bladder, papillary renal cell carcinoma, papillary endometrioid carcinoma ... Breast carcinomas Vaginal, cervical and/or endometrial neoplasms Papillary neoplasms of several organs: ... It can be present in: Thyroid neoplasms: It is a characteristic feature of papillary thyroid carcinoma, but has also been seen ... in other types of thyroid neoplasms, as well as in non-neoplastic thyroid lesions. Ovarian tumors including Brenner tumors, ...
... neoplasms of the urinary bladder. Bladder Consensus Conference Committee". The American Journal of Surgical Pathology. 22 (12 ... Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. Symptoms include blood in the ... "Cancer of the Urinary Bladder - Cancer Stat Facts". SEER. Retrieved 30 October 2019. "Bladder Cancer Factsheet" (PDF). Global ... The treatment of bladder cancer depends on how deeply the tumor invades into the bladder wall. Treatment strategies for bladder ...
Intravesical infusion is into the urinary bladder. Intravitreal, through the eye. Subcutaneous (under the skin). This generally ... Intraocular, into the eye, e.g., some medications for glaucoma or eye neoplasms. Intraosseous infusion (into the bone marrow) ...
Associated with cystitis glandularis, a precursor to adenocarcinoma of the urinary bladder. Prabakaran, Rudreshwar; Abraham, ... Pelvic lipomatosis: a condition simulating pelvic neoplasm. Radiology. 1968;90:558. http://www.medscape.com/viewarticle/417016_ ...
Cancer of the urinary organs (Renal cell carcinoma, Bladder cancer) Kurman, Robert J. (2013). Blaustein's Pathology of the ... A urogenital neoplasm is a tumor of the urogenital system. Types include: Cancer of the breast and female genital organs: ( ...
Bladder Pain, and the Interstitial Cystitis/Bladder Pain Syndrome Chapter 48: Azotemia and Urinary Abnormalities Chapter 49: ... Neoplasms of the Lung Chapter 75: Breast Cancer Chapter 76: Upper Gastrointestinal Tract Cancers Chapter 77: Lower ... Cancer of the Bladder and Urinary Tract Chapter 83: Benign and Malignant Diseases of the Prostate Chapter 84: Testicular Cancer ... Atlas of Urinary Sediments and Renal Biopsies Chapter A4: Atlas of Skin Manifestations of Internal Disease Chapter A5: Atlas of ...
... urinary bladder and part of the urethra. PUNLMP is pronounced pun-lump, like the words pun and lump. As their name suggests, ... Papillary urothelial neoplasm of low malignant potential (PUNLMP) is an exophytic (outward growing), (microscopically) nipple- ... MacLennan GT, Kirkali Z, Cheng L (April 2007). "Histologic grading of noninvasive papillary urothelial neoplasms". Eur. Urol. ... PUNLMPs are neoplasms, i.e. clonal cellular proliferations, that are thought to have a low probability of developing into ...
... is cancer of the ureters, muscular tubes that propel urine from the kidneys to the urinary bladder. It is also ... females..." Ureteral neoplasm, a type of tumor that can be primary, or associated with a metastasis from another site Urethral ... After surgery to remove the tumor, a single dose of chemotherapy injected into the bladder is helpful in reducing the rate of ... Transitional cell carcinoma is "a common cause of ureter cancer and other urinary (renal pelvic) tract cancers." Symptoms of ...
... other male genital organs 188 Malignant neoplasm of bladder 189 Malignant neoplasm of kidney and other and unspecified urinary ... 140 Malignant neoplasm of lip 141 Malignant neoplasm of tongue 142 Malignant neoplasm of major salivary glands 143 Malignant ... of male genital organs 223 Benign neoplasm of kidney and other urinary organs 224 Benign neoplasm of eye 225 Benign neoplasm of ... benign neoplasm of uterus 220 Benign neoplasm of ovary 221 Benign neoplasm of other female genital organs 222 Benign neoplasm ...
... bladder infection, indigestion Obstruction: kidney stones, urolithiasis, urinary retention, tumours Vascular: left renal vein ... benign or malignant neoplasms Large bowel obstruction caused by colorectal cancer, inflammatory bowel disease, volvulus, fecal ... complicated urinary tract infection Left low back pain Spleen Kidney: kidney stone (nephrolithiasis), complicated urinary tract ... bladder stone, bladder cancer, pelvic inflammatory disease, pelvic pain syndrome Gynecologic: endometriosis, intrauterine ...
... urinary tract infection, medication, porphyria, intra-abdominal bleeding, vaginal bleeding, neoplasm located in either bladder ... For instance, cloudy or milky urine usually accompanied by bad smell possibly indicates urinary tract infection, excessive ... and urinary tract infections. Doctor may prescribe some tests to help get the full picture of the situation, such as blood ... tests, liver function tests, ultrasound for kidneys and bladder, urinalysis, urine culture for infection, and cystoscopy. ...
Its used is in the treatment of overactive bladder. It works equally well to antimuscarinic medication such as solifenacin or ... Other significant side effects include urinary retention, irregular heart rate, and angioedema. It works by activating the β3 ... Sinusitis Diarrhea High heart rate Fatigue Abdominal pain Neoplasms (cancers) Rare (. ... Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits ...
Symptoms include: infection, bladder dysfunction, abdominal pain, vaginal discharge, and urinary incontinence. It is often ... "Benign Neoplasms of the Vagina , GLOWM". www.glowm.com. Retrieved 2018-03-01. Jayaprakash, Sheela; M, Lakshmidevi; G, Sampath ... Vaginal cysts can also be congenital and associated with urinary system anomalies The most common type of vaginal cyst are ... large enough to cause urinary incontinence but surgical removal provides treatment and recurrence is unlikely. Diagnosis is ...
Bladder and bowel dysfunction, caused by decreased tone of the urinary and anal sphincters. Detrusor weaknesses causing urinary ... with spinal neoplasms chemotherapy can also be used. If the syndrome is due to an inflammatory condition e.g., ankylosing ... Urinary catheterization may help with bladder control. Gravity and exercise can help control bowel movement (Hodges, 2004). ... Changes in bladder function may be changes to stream or inability to empty bladder fully. If a person progresses to full ...
Lower urinary tract obstruction (such as that caused by bladder outflow obstruction secondary to prostatic hypertrophy) is ... In older adults, the most common cause of hydronephrosis is benign prostate hyperplasia (BPH), or intrapelvic neoplasms such as ... Common causes include bladder dysfunction (such as neurogenic bladder) and urethral obstruction (such as posterior urethral ... Acute obstruction of the upper urinary tract is usually treated by the insertion of a nephrostomy tube. Chronic upper urinary ...
... lines the organs of the urinary system and is known here as urothelium. The bladder for example has a ... Papillary urothelial lesions Papillary urothelial hyperplasia Urothelial papilloma Papillary urothelial neoplasm of low ... Patients with advanced bladder cancer or disease, also often look to bladder reconstruction as a treatment. Current methods of ... "Bladder cancer risk factors". Cancer Research UK. Retrieved 27 July 2014. American Cancer Society. (2014). Bladder cancer. ...
... urinary bladder of infants and young children or the vagina in females, typically younger than age 8. The name comes from the ... Neoplasms of the Vulva and Vagina. in Holland-Frei Cancer Medicine - 6th Ed. Kufe, DW et al. editors. BC Decker Inc., Hamilton ...
... also is found in medical terms that relate to the urinary bladder and the gallbladder, neither of which involve cysts. ... Cystic neoplasmEdit. Examples of neoplastic cysts include: *Dermoid cyst. *Keratocystic odontogenic tumor ...
It can involve the urinary bladder, but is not bladder cancer in the usual sense. Urachal cancer can occur at any site along ... "Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin". Advances in Anatomic ... No findings of cystitis glandularis on the bladder surface. These findings can be precursor lesions of a primary bladder ... "The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours". ...
Bladder cystoscopy is performed to detect if there is simultaneous bladder cancer. Types of urethral cancer include the most ... The World Health Organization classification of tumours of the urinary system and male genital organs (4th edn) was published ... "Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization ... Risk factors suggested include prolonged irritations of the urethra due to urinary catheterization, chronic inflammation due to ...
... urinary bladder, lung, breast, fallopian tubes, and the pancreas. This disease is often discovered during surgery for other ... For example, neoplasms characterized by high-grade features, invasive glands and or signet ring cells, are termed ... Young R (2004). "Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms". Semin Diagn Pathol ... ISBN 978-0-323-35909-2. Sugarbaker P (2006). "New standard of care for appendiceal epithelial neoplasms and pseudomyxoma ...
Acquired abnormalities if the FGFR1 gene are found in: ~14% of urinary bladder Transitional cell carcinomas (almost all are ... These neoplasms were initially regarded as eosinophilias, hypereosinophilias, Myeloid leukemias, myeloproliferative neoplasms, ... Unlike many other myeloid neoplasms with eosinophil such as those caused by Platelet-derived growth factor receptor A or ...
"The sign of Leser-Trélat associated with transitional cell carcinoma of the urinary-bladder--a case report and short review". ... It is likely that various cytokines and other growth factors produced by the neoplasm are responsible for the abrupt appearance ... Although most associated neoplasms are gastrointestinal adenocarcinomas (stomach, liver, colorectal and pancreas), malignancies ... of the breast, lung, and urinary tract, as well as lymphoid tissue, have been associated with this impressive rash. ...
The dye travels from the blood stream and into the kidneys which in time, passes into the kidneys and bladder. This test is not ... For small exophytic lesions that do not extensively involve the major vessels or urinary collecting system, a partial ... which is an assessment based on the microscopic morphology of a neoplasm with haematoxylin and eosin (H&E staining). This ... is a useful procedure in detecting the presence of abnormal renal mass in the urinary tract. This procedure involves the ...
PAX gene deficiencies can result in development defects called Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). ... aka Hurthle-Cell Neoplasms).[15] Tumors expressing the PAX8/PPARy are usually present in at a young age, small in size, present ... bladder, prostate, and endometrial carcinomas.[9] The mechanism of switching on the genes is unknown. Some studies have ...
Bladder emptying was significantly improved, while there was a trend towards a higher urinary flow and shorter voiding time.[ ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... Cystoscopy shows the urinary tract from inside the bladder, using a thin, flexible camera tube inserted down the urethra. ... under the urinary bladder and in front of the rectum. The prostate surrounds part of the urethra, the tube that carries urine ...
Symptoms may include lower urinary tract symptoms associated with stenosis of the urethra, painful sexual intercourse, and ... bladder and conjunctiva of the eyes.[11][12][13] ... Salivary gland neoplasms *Benign: Basal cell adenoma. * ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... "Screening for Bladder Cancer". U.S. Preventive Services Task Force. 2004. Archived from the original on 23 August 2010.. ... Colon, uterine, small bowel, stomach, urinary tract Genetic testing for individuals at high-risk of certain cancers is ... Routine screening is not recommended for bladder cancer,[136] testicular cancer,[137] ovarian cancer,[138] pancreatic cancer,[ ...
en:Lower urinary tract symptoms (5). *en:Low molecular weight heparin (9) ... en:Neoplasm (40) → 신생물 *en:Nephrotic syndrome (38) → 신증후군 *en:Nervous system disease (4) ... en:Bladder cancer (37) → 방광암 *en:Blood in stool (7). *en:Blue baby syndrome (8) ...
Polyps are commonly found in the colon, stomach, nose, ear, sinus(es), urinary bladder, and uterus. They may also occur ... Some polyps are tumors (neoplasms) and others are nonneoplastic (for example, hyperplastic or dysplastic). The neoplastic ones ...
Many type of cancers, including colorectal cancer and cancer of the urinary bladder, may cause acute or chronic blood loss, ... and a number of neoplasms of the bone marrow.[1] Causes of increased breakdown include a number of genetic conditions such as ...
"Plasma Cell Neoplasms (Including Multiple Myeloma)-Patient Version". NCI. 1980-01-01. Archived from the original on 27 July ... Finally, radicular pain, loss of bowel or bladder control (due to involvement of spinal cord leading to cord compression) or ... which is a urinary paraprotein composed of free light chains. Quantitative measurements of the paraprotein are necessary to ... "Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment". National Cancer Institute. 1980-01-01. Retrieved 28 November ...
The uterus is located in the pelvis immediately dorsal (and usually somewhat cranial) to the urinary bladder and ventral to the ... fibroids - benign neoplasms. The term "uterus" is commonly used within the medical and related professions, whilst the term ...
Bladder emptying was significantly improved, while there was a trend towards a higher urinary flow and shorter voiding time.[ ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... Cystoscopy shows the urinary tract from inside the bladder, using a thin, flexible camera tube inserted down the urethra. ... under the urinary bladder and in front of the rectum. The prostate surrounds part of the urethra, the tube that carries urine ...
Intravesical infusion is into the urinary bladder.. *intravitreal, through the eye. *Subcutaneous (under the skin).[22] This ... intraocular, into the eye, e.g., some medications for glaucoma or eye neoplasms ...
Urinary bladder disease(英語:Urinary bladder disease). *Male genital disease(英語:Male genital disease) ... 癌症(C00-D48, 140-239(英語:List of ICD-9 codes 140-239: neoplasms)). *腫瘤 ...
The liver, gall bladder, spleen, pancreas, duodenum, colon, and kidneys are routinely evaluated in all patients. ... and left-sided colorectal neoplasms after colonoscopy: population-based study". J Natl Cancer Inst. 102 (2): 89-95. doi:10.1093 ...
Changes in bowel and bladder habits, particularly urinary retention with overflow incontinence, usually occur late in the ... Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are (at least eventually) very dangerous and life ... and the specific type of malignant brain neoplasm. Surgery may in some cases be curative, but, as a general rule, malignant ... Meningioma assecond malignant neoplasm after oncological treatment during childhood. 188, 438-441. Retrieved from http://www. ...
The seminal vesicles are a pair of glands in males that are positioned below the urinary bladder and at the end of the vasa ... Even rarer neoplasms include sarcoma, squamous cell carcinoma, yolk sac tumor, neuroendocrine carcinoma, paraganglioma, ... They lie in the space between the bladder and the rectum; the bladder and prostate lie in front, the tip of the ureter as it ... The Urinary Bladder" Anatomy photo:44:08-0103 at the SUNY Downstate Medical Center - "The Male Pelvis: Structures Located ...
Cystoscopy shows the urinary tract from inside the bladder, using a thin, flexible camera tube inserted in the urethra. ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... The prostate surrounds the urethra, a muscular tube that closes the urinary bladder. Any of the mentioned reasons can lead to ... Samuel David Gross (1851). A Practical Treatise On the Diseases and Injuries of the Urinary Bladder, the Prostate Gland, and ...
... protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder". Pharmacol. Res. 151: ... for pemigatinib for the treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 ...
Some published studies found a reduction in long term rectal and genito-urinary damage when treating with protons rather than ... Two prominent examples are pediatric neoplasms (such as medulloblastoma) and prostate cancer. Irreversible long-term side ... gastrointestinal and bladder side effects. Proton therapy for ocular (eye) tumors is a special case since this treatment ... bladder and other tissues anterior to the vertebrae is eliminated, resulting in a reduction of acute thoracic, ...
Kidney stones can be present along any part of the course of the urinary tract from the kidneys to the urethra. The most common ... which can result in loss of blood flow to surrounding areas of the bladder or rectum. Data suggests that TURP may have higher ... such as osteoporosis or underlying neoplasm. Analogous to vertebroplasty, the purpose of sacroplasty is to provide ... However, TURP can lead to urinary incontinence or permanent male infertility and may not be the ideal procedure for a certain ...
... as several antineoplastic drugs are known to cause bladder damage. Urinary mutagenicity is a marker of exposure to ... Survivors of childhood cancer are more than 13 times as likely to get a secondary neoplasm during the 30 years after treatment ... Biomarkers of exposure to antineoplastic drugs commonly include urinary platinum, methotrexate, urinary cyclophosphamide and ... The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with ...
PAX gene deficiencies can result in development defects called Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). ... bladder, prostate, and endometrial carcinomas. Tumors expressing the PAX8/PPARy are usually present in at a young age, small in ... aka Hurthle-Cell Neoplasms). Expression of PAX8 is increased in neoplastic renal tissues, Wilms tumors, ovarian cancer and ...
KEYWORDS: Urinary bladder neoplasms, X-ray computed tomography, neoplasm staging. CORRESPONDENCE: Ashish M. Kamat, Department ... Autophagy and urothelial carcinoma of the bladder: A review. The incidence of urothelial carcinoma of the urinary bladder ( ... Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. Standard management of muscle-invasive bladder ... Can laparoscopic cystectomy become the method of choice in the treatment of invasive urothelial urinary bladder cancer? Radical ...
All MeSH CategoriesDiseases CategoryNeoplasmsNeoplasms by SiteUrogenital NeoplasmsUrologic NeoplasmsUrinary Bladder Neoplasms ... "urinary bladder neoplasms"[MeSH Terms] OR Urinary Bladder Neoplasms[Text Word]. Search. ... All MeSH CategoriesDiseases CategoryMale Urogenital DiseasesUrologic DiseasesUrinary Bladder DiseasesUrinary Bladder Neoplasms ... All MeSH CategoriesDiseases CategoryMale Urogenital DiseasesUrogenital NeoplasmsUrologic NeoplasmsUrinary Bladder Neoplasms ...
... bladder cancer , Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms ... Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms Brief description of study. The purpose of this ... By enrolling patients with unresectable Urinary Bladder Neoplasms adapted to enrolled criteria, this study will document for ... efficacy of percutaneous IRE for unresectable Urinary Bladder Neoplasms. ...
... and the International Consultation on Urological Diseases-European Association of Urology updates on bladder cancer. ... Grading and staging of urothelial neoplasm are the most crucial factors in risk stratification and management; both necessitate ... Contemporary Grading and Staging of Urothelial Neoplasms of the Urinary Bladder: New Concepts and Approaches to Challenging ... Grading and staging of urothelial neoplasm are the most crucial factors in risk stratification and management; both necessitate ...
Malignant Neoplasm Of Genitourinary Organs 179-189 > Malignant neoplasm of bladder 188- ... 2015/16 ICD-10-CM C67.3 Malignant neoplasm of anterior wall of bladder ... Cancer of the urinary bladder, anterior wall. *Primary malignant neoplasm of anterior wall of urinary bladder ...
In 68 patients with suspected urinary bladder neoplasms, MR examinations were performed with T1-weighted SE sequences before ... Contrast enhancement increased the sensitivity for detection of urinary bladder neoplasms from 70% on precontrast T1-weighted ... intravenous administration of Gd-DTPA can improve the accuracy of MR imaging in the detection and staging of bladder neoplasms ... in tumors without muscular bladder wall invasion (Ta). In cases with extravesical spread (greater than or equal to T3b), the ...
Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms. Conditions: Urinary Bladder Neoplasms ... Urinary Bladder Neoplasm Intervention: Laser En Bloc Resection Of Bladder Tumor, Electro-surgical En Bloc Resection Of Bladder ... uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer. Conditions: Urinary Bladder Neoplasms Intervention: ... The Bladder Instillation Comparison Study. Conditions: Urinary Bladder Neoplasms Intervention: Mitomycin C, Gemcitabine ...
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
... neoplasms, registries, risk assessment, second primary, tobacco, urinary bladder neoplasms ... neoplasms, registries, risk assessment, second primary, urinary bladder neoplasms ... non-muscle-invasive bladder cancer, transurethral resection, urinary bladder neoplasms ... Impact of bladder cancer on health‐related quality of life, patient‐reported outcomes, treatment outcome, urinary bladder ...
"Urinary Bladder Neoplasms" by people in this website by year, and whether "Urinary Bladder Neoplasms" was a major or minor ... "Urinary Bladder Neoplasms" by people in Profiles.. * Hwang MJ, Kamat AM, Dinney CP, Czerniak B, Guo CC. Bladder Cancer ... "Urinary Bladder Neoplasms" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Urinary Bladder Neoplasms*Urinary Bladder Neoplasms. *Neoplasm, Urinary Bladder. *Urinary Bladder Neoplasm ...
Urinary Bladder Neoplasms Trials Filters Clear Filters .btn-group .dropdown-menu .dropdown-items { max-height: 350px; min-width ... Bladder Cancer Clinical Trial NCT01489813 - Phase 2 - Interventional Patients with non-invasive bladder cancer are often ... Bladder Cancer Clinical Trial. Recruiting - NCT00001823. Bladder Cancer Clinical Trial. Recruiting - NCT00026884. ... risk superficial bladder cancer (cancer not yet involving the muscle of the bladder wall) who have had r... ...
"Urinary bladder neoplasms". 0-9. A. B. C. D. E. F. G. H. I. J. K. L. M. N. O. P. Q. R. S. T. U. V. W. X. Y. Z. * 0-9 ...
Malignant Neoplasm of the Urinary Bladder Stage 4B: Read more about Symptoms, Diagnosis, Treatment, Complications, Causes and ...
Best hospitals and doctors for Urinary Bladder Neoplasms at Medizinische Universitat Wien ... For example, Shahrokh Shariat is the top-rated expert in Urinary Bladder Neoplasms at Medizinische Universitat Wien. ...
Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a ... Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a ... Papillary urothelial neoplasm of low malignant potential of the urinary bladder : clinicopathologic and outcome analysis from a ... title = "Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome ...
Best hospitals and doctors for Urinary Bladder Neoplasms at University of Texas Houston ... For example, Shahrokh Shariat is the top-rated expert in Urinary Bladder Neoplasms at the University of Texas Houston. ...
May be caused by smoking, exposure to certain cancer-causing chemicals, long term irritation to bladder caused by radiation or ...
Urinary Bladder Neoplasms. D001749. EFO:0000292. bladder carcinoma. 3. ClinicalTrials. Digestive System Diseases. D004066. EFO: ... Prostatic Neoplasms. D011471. EFO:0001663. prostate carcinoma. 3. ClinicalTrials. Urinary Tract Infections. D014552. EFO: ... Neoplasms. D009369. EFO:0000616. neoplasm. 1. ClinicalTrials. Plague. D010930. EFO:0007481. septicemic plague. 2. ... Rectal Neoplasms. D012004. EFO:1000657. rectum cancer. 2. ClinicalTrials. Anthrax. D000881. EFO:0000778. anthrax infection. 2. ...
Urinary Bladder Neoplasms. D001749. EFO:0000292. bladder carcinoma. 2. ClinicalTrials. Adenocarcinoma, Follicular. D018263. EFO ... Urethral Neoplasms. D014523. EFO:0003846. urethral neoplasm. 2. ClinicalTrials. Colorectal Neoplasms. D015179. EFO:0000365. ... Neoplasms. D009369. EFO:0000616. neoplasm. 4. ATC. ClinicalTrials. Retinal Diseases. D012164. EFO:0003839. retinopathy. 2. ... Ovarian Neoplasms. D010051. EFO:0003893. ovarian neoplasm. 2. ClinicalTrials. Retinal Vein Occlusion. D012170. EFO:1001157. ...
Urinary Bladder Liang Cheng, Antonio Lopez-Beltran. Pages 1681-1735 * Renal Pelvis, Ureter, and Urethra ... Neoplasms of the Skin and Immunodermatology Daniel P. Vandersteen, Chris H. Jokinen ...
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of ... ClinicalTrials.gov: Urethral Neoplasms (National Institutes of Health) * ClinicalTrials.gov: Urinary Bladder Neoplasms ( ... The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It ... General Information about Bladder Cancer (National Cancer Institute) Also in Spanish * What Is Bladder Cancer? (American Cancer ...
Neoplasms. Ureteral Neoplasms. Urinary Bladder Neoplasms. Urethral Neoplasms. Kidney Neoplasms. Carcinoma. Neoplasms, Glandular ... Urologic Neoplasms. Urogenital Neoplasms. Neoplasms by Site. Ureteral Diseases. Urologic Diseases. Urinary Bladder Diseases. ... Bladder cancer is the fourth most common malignancy in men and the ninth most common in women in the US, with an estimated ... bladder cancer. renal pelvis cancer. ureters cancer. urethra cancer. HLA-A2 positive. HLA-A*0201/p53 aa264-272. HLA complex. ...
Lung Neoplasms. Pancreatic Neoplasms. Stomach Neoplasms. Head and Neck Neoplasms. Uterine Cervical Neoplasms. Urinary Bladder ... Kidney Neoplasms. Carcinoma, Renal Cell. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung ... Uterine Neoplasms. Genital Neoplasms, Female. Urogenital Neoplasms. Uterine Cervical Diseases. Uterine Diseases. ... Digestive System Neoplasms. Endocrine Gland Neoplasms. Digestive System Diseases. Pancreatic Diseases. Endocrine System ...
Urinary Bladder Neoplasms. Urologic Neoplasms. Urogenital Neoplasms. Neoplasms by Site. Neoplasms. Urinary Bladder Diseases. ... BCG Refractory or Relapsed Superficial Bladder Cancer. rAd-IFN. Syn3. Intravesical. transitional cell carcinoma of the bladder ... Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. The safety and ... Existing urinary tract infection or bacterial cystitis. *Clinically significant and unexplained elevated liver or renal ...
Colorectal Neoplasms. Head and Neck Neoplasms. Urinary Bladder Neoplasms. Triple Negative Breast Neoplasms. Kidney Neoplasms. ... Bronchial Neoplasms. Lung Neoplasms. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung ... Intestinal Neoplasms. Gastrointestinal Neoplasms. Digestive System Neoplasms. Digestive System Diseases. Gastrointestinal ... urinary bladder, and urethra, not previously treated with anti-PD-L1/PD-1 with or without anti-CTLA-4 (investigational or ...
Classification and Differential Diagnosis of Neoplasms, Urinary Bladder, Rat Robert A. Squire ...
Therapy Related Neoplasms in Hematopathology Conference scheduled on June 03-04, 2022 in June 2022 in New York is for the ... Urinary bladder. Lung disease. Bronchial disease. Infectious diseases. Neoplasia. Congenital anomalies. Surgical and autopsy ... Therapy Related Neoplasms in Hematopathology. ICTRNH 2022: 16. International Conference on Therapy Related Neoplasms in ... ICTRNH 2022 has teamed up with the Special Journal Issue on Therapy Related Neoplasms in Hematopathology. A number of selected ...
Urinary Bladder Non-invasive Urothelial Neoplasms Papillary Urothelial Neoplasm of Low Malignant Potential ... Non-benign category of papillary urothelial neoplasm with negligible risk of progression. ...
Neoplasm Proteins / biosynthesis* * Time Factors * Tumor Cells, Cultured * Urinary Bladder Neoplasms / metabolism* ... The suitability of in vitro bladder tumor culture models to study complex biological phenomena such as malignancy and invasion ... Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of ... 2-D PAGE immunoblotting and comparison with the bladder TCC protein database available on the internet (http://biobase.dk/cgi- ...
  • CT texture analysis in bladder carcinoma: histologic grade characterization]. (urotoday.com)
  • Objective: To explore the value of CT texture analysis (CTTA) in differentiating the pathological grade of urothelial carcinoma of the bladder (UCB). (urotoday.com)
  • Methods: A total of 53 lesions from 43 patients with bladder cancer confirmed by postoperative pathology were retrospectively analyzed, including 27 cases of high-grade urothelial carcinoma (HGUC) and 26 cases of low-grade urothelial carcinoma (LGUC). (urotoday.com)
  • Article of the week: How useful is FDG-PET/CT in managing carcinoma invading bladder muscle? (bjuinternational.com)
  • group I, WHO grade 1 and papillary urothelial neoplasm of low malignant potential by ISUP (7 cases), group II, WHO grade 2 and low-grade papillary urothelial carcinoma (16 cases), and group III, WHO grade 3 and high-grade papillary urothelial carcinoma (7 cases). (bvsalud.org)
  • The first neoplasm was a squamous cell carcinoma of the glottis diagnosed in 2006. (duhnnae.com)
  • The remaining three neoplasms were diagnosed in 2010, namely a squamous cell carcinoma of the oral floor, an adenocarcinoma of the prostate, and a squamous cell carcinoma of the esophagus. (duhnnae.com)
  • Squamous cell carcinoma of the urinary bladder is a malignant neoplasm derived from bladder urothelium with pure squamous phenotype. (medscape.com)
  • Because many urothelial carcinomas contain a minor squamous cell component, a diagnosis of squamous cell carcinoma of the bladder should be rendered only when the tumor is solely composed of a squamous cell component in the absence of a conventional urothelial carcinoma component. (medscape.com)
  • In the United States, squamous cell carcinoma constitutes around 5% of all urinary bladder carcinomas. (medscape.com)
  • Worldwide, the incidence of squamous cell carcinoma of the bladder varies. (medscape.com)
  • The highest incidence has been seen in areas where schistosomiasis is endemic, notably Sudan and Egypt, where squamous cell carcinoma ranges from two thirds to three quarters of all malignant tumors of the bladder. (medscape.com)
  • Having bladder diverticula may increase the likelihood that an individual will develop squamous cell carcinoma. (medscape.com)
  • [ 12 ] Bladder exstrophy has been associated with the development of squamous cell carcinoma at a younger age than usual. (medscape.com)
  • Smoking has a well-recognized role in the development of bladder carcinoma, with smoking duration and intensity directly related to increased risk. (medscape.com)
  • Cyclophosphamide chemotherapy has also been reported to increase the incidence of squamous cell carcinoma of the bladder. (medscape.com)
  • As previously mentioned, schistosomiasis is the major cause of squamous cell carcinoma of the bladder in African countries. (medscape.com)
  • In one study from Egypt, 82% of patients with bladder carcinoma were found to harbor Schistosoma haematobium eggs in the bladder wall. (medscape.com)
  • Plasmacytoid urothelial carcinoma of the urinary bladder: a clinical pathological study and literature review. (biomedsearch.com)
  • PURPOSE: Plasmacytoid carcinoma of the urinary bladder or plasmacytoid urothelial carcinoma (PUC) is a rare and only recently described histological variant of transitional cell carcinoma (TCC). (biomedsearch.com)
  • Small cell carcinoma of the urinary bladder. (biomedsearch.com)
  • [ 3 ] Worldwide, however, squamous cell carcinoma is the most common form of bladder cancer, accounting for up to 73% of cases in developing nations, particularly regions with a high prevalence of schistosomiasis (eg, Middle East, Southeast Asia, South America). (medscape.com)
  • For more information, see Bladder Cancer , as well as Pathologic Findings in Small Cell Bladder Carcinoma and Cystoscopy . (medscape.com)
  • Cystoscopically, squamous cell carcinoma appears nodular and has a plaquelike, irregular surface with involvement of multiple bladder sites. (medscape.com)
  • Verrucous squamous cell carcinoma is a rare variant of squamous cell carcinoma of the bladder, accounting for less than 5% of the squamous cell carcinomas. (medscape.com)
  • A single case of basaloid squamous cell carcinoma of the bladder was reported in a 60-year-old woman with incontinence, intractable urinary tract infections (UTIs), and flat, cystoscopic lesions. (medscape.com)
  • Ever smokers with high arsenic exposure had significantly increased risks for bladder cancer and upper urinary tract urothelial carcinoma, and our findings suggest that arsenic exposure, cigarette smoking, and risk genotypes of VEGFA contribute to a higher risk of upper urinary tract urothelial carcinoma than of bladder cancer. (mdibl.org)
  • Instillation therapies for urothelial carcinoma of the upper urinary tract. (bioportfolio.com)
  • Traditionally, urothelial carcinoma of the upper urinary tract was a clear indication for radical nephroureterectomy with bladder cuff excision. (bioportfolio.com)
  • 1992) Transitional Cell Carcinoma of the Bladder Associated with Crohn's Disease: Case Report and Review of the Literature. (scirp.org)
  • 2003) An Unusual Way to Diagnose a Rare Case of Bladder Carcinoma in a Patient with Crohn's Disease. (scirp.org)
  • Retrospective analysis was performed on the clinical data of 16 cases who had bladder tumors around ureteral orifice and underwent transurethral resection using plasmakinetic needle electrode in Department of Urology, Peking University International Hospital from June 2015 to December 2019. (urotoday.com)
  • Tumors or cancer of the URINARY BLADDER. (nih.gov)
  • Our study evaluates the behavior of these tumors occurring as primary urinary bladder lesions. (elsevier.com)
  • Bladder cancer develops when tumors form in the tissue that lines the bladder. (medlineplus.gov)
  • We assessed diagnostic criteria among 38 spindle cell tumors of the urinary bladder and obtained follow-up in 36 patients. (elsevier.com)
  • Using its Guidelines for Carcinogen Risk Assessment published September 24, 1986 (51 FR 33992) the Carcinogenicity Peer Review Committee (CPRC) has classified bifenthrin as a Group C chemical, possible human carcinogen, based on urinary bladde r tumors in mice, but did not recommend assignment of a cancer potency factor Q* (Q star) for a linear quantitative cancer risk assessment, instead, the CPRC recommended the RfD approach. (fluoridealert.org)
  • Tumors of the urinary bladder were observed and initially reported as leiomyosarcomas. (fluoridealert.org)
  • Subsequently, the bladders were reviewed and the tumors showed a pattern of both epithelioid cells and spindle cells forming irregular vascular channels. (fluoridealert.org)
  • The tumors appeared to arise from the trigone of the bladder and, in some cases, invaded the bladder wall. (fluoridealert.org)
  • Most of the tumors are large, exophytic, and necrotic and bulge into the bladder cavity. (medscape.com)
  • 2,3] Bladder cancer poses a significant economic burden due to the cost of the lifetime need for surveillance, the need to treat recurrent tumors, and the cost of complications associated with treatment. (cancernetwork.com)
  • Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. (iospress.com)
  • The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of tumors of the bladder and upper urinary tract. (iospress.com)
  • Three pairs of bladder carcinomas (including high- and low-grade tumors) and adjacent normal tissues were collected from patients. (medscimonit.com)
  • Hierarchical clustering analyses on these RNAs and their predicted mRNA targets showed that the majority of differentially expressed circRNAs and mRNAs had been up-regulated in the bladder tumors. (medscimonit.com)
  • by transurethral resection of bladder tumors (TURBT). (cdc.gov)
  • J. I. Epstein, "The New World Health Organization/International Society of Urological Pathology (WHO/ISUP) Classification for TA, T1 Bladder Tumors: Is It an Improvement? (scirp.org)
  • Even after superficial tumors are completely removed, there is a 75% chance that new tumors will develop in other areas of the bladder. (thefreedictionary.com)
  • A past history of tumors in the bladder also could increase one's risk of getting other tumors. (thefreedictionary.com)
  • Some polyps are tumors (neoplasms) and others are non-neoplastic, for example hyperplastic or dysplastic. (wikipedia.org)
  • Thirty percent of bladder tumors probably result from occupational exposure in the workplace to carcinogens. (wikipedia.org)
  • We report on the case of a 58-year-old male with multiple primary malignant neoplasms, who suffered from three histological types of malignant neoplasm in six organs, namely the glottis, renal pelvis, urinary bladder, oral floor, prostate, and esophagus in chronological order. (duhnnae.com)
  • The malignant neoplasms of the oral floor and those which originated in the urinary tract were surgically resected. (duhnnae.com)
  • As far as we know, the present report is the first one on this combination of primary malignant neoplasms. (duhnnae.com)
  • 202 ...................................... Other malignant neoplasms of lymphoid and histiocytic tissue. (cdc.gov)
  • Following improvements in therapy for childhood malignancies , the striking increase in survival rate over the past 30 years has led to the increase risk of developing second malignant neoplasms (SMNs). (bvsalud.org)
  • How do we improve the overall health of patients with bladder cancer? (bjuinternational.com)
  • The purpose of the study to compare two established methods of radical cystectomy (RC) in patients with bladder cancer. (centerwatch.com)
  • Muscle sampling is often used as a surrogate for staging quality in patients with bladder cancer. (cdc.gov)
  • We examined the association of staging quality at diagnosis and survival among patients with bladder cancer. (cdc.gov)
  • Because urologists cannot reliably discern between high- and low-grade or Ta and T1 disease, we contend that patients with bladder cancer should undergo adequate muscle sampling at the time of endoscopic resection. (cdc.gov)
  • We reviewed the medical records of 1865 patients with bladder cancer in Los Angeles County and found that suboptimal staging in nearly half of all diagnostic resections was associated with increased mortality, particularly in patients with high-grade disease. (cdc.gov)
  • Despite the vertiginous pace of technological advancement in medicine, treatment of patients with bladder cancer remains largely dependent on the unique anatomic properties of the bladder—being readily accessible to visual inspection, endoscopic resection, and instillation of intravesical agents. (cdc.gov)
  • The perioperative nursing care planning for patients with bladder cancer needs scientific knowledge and incorporation of technology. (scielo.org.co)
  • This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisplatin and gemcitabine or containing gemcitabine alone in patients who have muscle invasive or metastatic urothelial cancer of bladder, renal pelvis, ureters and urethra. (clinicaltrials.gov)
  • The second and third neoplasms were urothelial carcinomas of the right renal pelvis and urinary bladder, respectively, diagnosed in 2008. (duhnnae.com)
  • The subtypes are classified by the degree of leakage, descent and opening of the bladder neck and URETHRA without bladder contraction, and sphincter deficiency. (bioportfolio.com)
  • The urethra carries the urine from the bladder to the outside of the body. (thefreedictionary.com)
  • The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of. (nih.gov)
  • We describe a technique of bladder neck detachment and augmented closure incorporating total prostatectomy and urinary diversion in men with complex bladder and urethral pathology due to fistula , radiation and neurogenic dysfunction. (curehunter.com)
  • Prostatectomy facilitated mobilization of the bladder neck away from the urethral pathology and interposition of an intestinal segment at the bladder neck allowed healing. (curehunter.com)
  • Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. (medlineplus.gov)
  • Researchers have identified many lifestyle and environmental factors that expose individuals to cancer-causing compounds (carcinogens), which increase the rate at which somatic mutations occur, contributing to a person's risk of developing bladder cancer. (medlineplus.gov)
  • The p53 protein is one of the most important factors that protects from developing cancer and is also one of the most frequently mutated genes in many cancers, which include muscle-invasive bladder cancer. (clinicaltrials.gov)
  • Somatic mutations in the FGFR3 , PIK3CA , KDM6A , and TP53 genes are common in bladder cancers. (medlineplus.gov)
  • Medicare estimates have ranked bladder cancer treatment the seventh costliest among cancers, with a 5-year net cost of approximately one billion dollars. (cancernetwork.com)
  • Besides kidney transplants, Dr. Ghasemian offers surgical treatment for diabetes, treats urology issues for pre-and post-transplant patients as well as bladder, kidney and prostate cancers. (medstarhealth.org)
  • This study suggests lower bladder cancer risks for arsenic than predicted from other studies but adds to evidence that the latency for arsenic-induced bladder cancers may be longer than previously thought. (mdibl.org)
  • Bladder cancer is one of the most frequent cancers in high-income countries. (minervamedica.it)
  • Bladder cancer represents a health burden in Italy, with high incidence and prevalence rates, and important unmet needs for patients, including the limited therapeutic options for advanced/metastatic cancers, the low quality of life after radical cystectomy, the lack of widespread clinical pathway schemes, and the low patients empowerment. (minervamedica.it)
  • Thioplex is a prescription medication used to treat certain types of ovarian, breast, and bladder cancers. (rxwiki.com)
  • In 2003, studies showed that hormone replacement therapy (HRT), a treatment used by many postmenopausal women, significantly increased the risk of bladder and other cancers. (thefreedictionary.com)
  • Blood in the urine may also be caused by other conditions, such as bladder or ureteric stones, infection, kidney disease, kidney cancers or vascular malformations, though these conditions (except kidney cancers) would typically be painful. (wikipedia.org)
  • Objective: To explore the application of Endo-GIA stapler in laparoscopic radical cystectomy, especially in the treatment of lateral bladder ligament, and to evaluate its clinical feasibility and practicability. (urotoday.com)
  • Radical cystectomy (RC) is a comprehensive surgery including pelvic lymph node dissection and urinary diversion. (centerwatch.com)
  • H. A. Frazier, J. E. Robertson and D. F. Paulson, "Complications of Radical Cystectomy and Urinary Diversion: A Retrospective Review of 675 Cases in 2 Decades," Journal of Urology, Vol. 148, No. 5, 1992, pp. 1401-1405. (scirp.org)
  • Radical Cystectomy in the Treatment of Invasive Bladder Cancer: LongTerm Results in 1054 Patients," Journal of Clinical Oncology, Vol. 19, No. 3, 2001, pp. 666-675. (scirp.org)
  • Radical Cystectomy for Bladder Cancer Today-A Homogeneous Series without Neoadjuvant Therapy," Journal of Clinical Oncology, Vol. 21, No. 4, 2003, pp. 690-696. (scirp.org)
  • To evaluate the performance of 3.0T magnetic resonance imaging examination (MRI) for the local detecting of muscle invasive bladder cancer following transurethral resection of bladder tumor (TURBT). (urotoday.com)
  • Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. (viictr.org)
  • Muscle invasive bladder cancer is life threatening. (clinicaltrials.gov)
  • This Phase 2 study is designed to assess the efficacy and safety of INSTILADRIN (rAd-IFN with Syn3) when given intravesically to patients with high grade non-muscle invasive bladder cancer who are refractory to or have relapsed from BCG therapy. (clinicaltrials.gov)
  • beyond the lining of the bladder into nearby tissues or organs, it is known as invasive bladder cancer. (medlineplus.gov)
  • Intravesical instillation of bacillus Calmette-Guérin (BCG) has been a first-line therapy for non-muscle-invasive bladder cancer for the last 4 decades. (bioportfolio.com)
  • 1] Of new cases, 70% to 80% present with non-muscle-invasive bladder cancer (NMIBC). (cancernetwork.com)
  • We reviewed the clinical records of all individuals within the Los Angeles SEER Registry with an incident diagnosis of non-muscle-invasive bladder cancer in 2004–2005. (cdc.gov)
  • Muscle-invasive bladder cancer portends a much worse prognosis than non-muscle-invasive disease and does not respond to intravesical therapy. (cdc.gov)
  • Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy," European Urology, Vol. 56, No. 3, 2009, pp. 430-442. (scirp.org)
  • The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for Instillation (VAX014) in patients with low-grade Non-Muscle Invasive Bladder Cancer (N. (bioportfolio.com)
  • A consecutive series of patients with High Risk Non-Muscle Invasive Bladder Cancer will be enrolled in several centres. (bioportfolio.com)
  • Smoking is an important risk factor for the development, recurrence and progression of bladder cancer. (urotoday.com)
  • Considering the low but definitive risk of recurrence and grade progression, appropriate clinical follow-up of patients with primary papillary urothelial neoplasm of low malignant potential is warranted. (elsevier.com)
  • MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer. (bioportfolio.com)
  • Bladder cancer is the most common urogenital tumor with substantial morbidity, high recurrence rate and mortality. (bioportfolio.com)
  • Management of NMIBC, traditionally, has been focused on the reduction of subsequent bladder recurrence and prevention of disease progression and is primarily based on transurethral resection (TUR) of the tumor, followed by intravesical therapy based on estimated individual risk of recurrence. (srce.hr)
  • To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer. (bioportfolio.com)
  • Bladder cancer has a very high rate of recurrence. (thefreedictionary.com)
  • Also, in the already conducted RCTs of ORC versus RARC the urinary diversion has been done extracorporally. (centerwatch.com)
  • All 5 patients underwent radical prostatectomy and augmented bladder neck closure with creation of a continent catheterizable stoma in 4 and chimney diversion in 1. (curehunter.com)
  • Surgical options may include transurethral resection, partial or complete removal of the bladder, or urinary diversion. (wikipedia.org)
  • In certain parts of the African continent, the majority of bladder carcinomas are of the squamous cell type. (medscape.com)
  • A higher degree of adenocarcinoma has also been reported in schistosomal-associated bladder carcinomas. (medscape.com)
  • Carcinogenic potential was evidenced by a statistically significant increased trend for hemangiopericytomas in the urinary bladders of males, a significant dose-related trend for combined hepatocellular adenomas and carcinomas in males, and a significantly higher incidence of combined lung adenomas and carcinomas in females. (fluoridealert.org)
  • In summary, we provide molecular epidemiologic evidence that supports strongly the hypothesis that, in genetically susceptible individuals, dietary exposure to aristolochic acid is causally related to endemic (Balkan) nephropathy and to the carcinomas of the upper urinary tract associated with this disease. (mdibl.org)
  • The patient was diagnosed with rhabdomyosarcoma of the urinary bladder at his age of three years, and developed adenocarcinoma in the colon 13 years later. (bvsalud.org)
  • Some rare forms of bladder cancer like urachal adenocarcinoma produce mucin, which is then excreted in the urine causing it to be thick. (wikipedia.org)
  • A Genomic-clinicopathologic Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. (urotoday.com)
  • Clinical application of the needle electrode in transurethral plasmakinetic resection of bladder tumor around ureteral orifice: A report of 16 cases]. (urotoday.com)
  • To explore the clinical application value of using needle electrode in transurethral plasmakinetic resection of bladder tumor around ureteral orifice. (urotoday.com)
  • [ 3 ] Transurethral resection of bladder tumor ( TURBT ) biopsies may contain only keratinous debris. (medscape.com)
  • Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply uncontrollably to form a tumor. (medlineplus.gov)
  • We conclude that the major impact of arsenic in drinking water on circulatory disease involves acute myocardial infarction and that, in the initial years, it is the main cause of death from arsenic in drinking water, superseded in later years by excess mortality from lung and bladder cancer. (mdibl.org)
  • A technique of bladder neck closure combining prostatectomy and intestinal interposition for unsalvageable urethral disease. (curehunter.com)
  • Recurrent lymphoma in the urinary bladder is associated with widely disseminated disease and poor prognosis [ 1 ]. (hindawi.com)
  • Advances in cancer immunotherapy and in understanding molecular biology of bladder cancer are, however, rapidly altering the therapeutic landscape for targeted subgroups of patients with advanced/metastatic disease. (minervamedica.it)
  • The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms. (bioportfolio.com)
  • Bladder cancer is a disease in which the cells lining the urinary bladder lose the ability to regulate their growth and start dividing uncontrollably. (thefreedictionary.com)
  • Although the exact cause of bladder cancer is not known, smokers are twice as likely as nonsmokers to get the disease. (thefreedictionary.com)
  • If a doctor has any reason to suspect bladder cancer, several tests can help find out if the disease is present. (thefreedictionary.com)
  • Joffe, N. (1976) Roentgenologic Abnormalities of the Urinary Bladder Secondary to Crohn's Disease. (scirp.org)
  • Merine, D., Fishman, E.K. and Huhlman, J.E. (1989) Bladder Involvement in Crohn's Disease: Role of CT in Detection and Evaluation. (scirp.org)
  • 2000) Crohn's Disease of the Bladder. (scirp.org)
  • Evans, C.E. and Tighe, M.P. (2014) Crohn's Disease Presenting as Bladder Mass. Archives of Disease in Childhood, 99, 256. (scirp.org)
  • Potential underlying conditions range from benign to severe malignant diseases of the kidneys and urinary tract. (urotoday.com)
  • Several updates and recommendations have been provided though recent publications of the 4th edition of the World Health Organization classification, the 8th edition of the American Joint Committee on Cancer staging system, and the International Consultation on Urological Diseases-European Association of Urology updates on bladder cancer. (urotoday.com)
  • Diseases associated with CCN4 include Bladder Papillary Transitional Cell Neoplasm and Urinary Tract Papillary Transitional Cell Benign Neoplasm . (genecards.org)
  • 3 ] reported long median survival for either primary lymphoma of bladder or lymphoma with initial presentation in the urinary bladder but other coexisting diseases [ 3 ]. (hindawi.com)
  • Non-benign category of papillary urothelial neoplasm with negligible risk of progression. (auanet.org)
  • It is likely that a loss of one or more of these genes plays a role in the early development and progression of bladder cancer. (medlineplus.gov)
  • Because of the tremendous detriment to patients' quality of life and the cost to society, minimally invasive treatments that can delay or prevent progression of bladder cancer are particularly attractive. (cancernetwork.com)
  • This study aimed to investigate the role and mechanism of circRNAs in the development and progression of bladder cancer. (medscimonit.com)
  • De Nunzio C, Giannatempo P, Passalacqua R, Fiorini E, Luccarini I, Brigido A. Epidemiology and unmet needs of bladder cancer in Italy: a critical review. (minervamedica.it)
  • Surgical intervention combined with intravesical instillation of chemotherapeutics to clear residual cancer cells after operation is the current standard treatment method for bladder cancer. (bioportfolio.com)
  • Few long-term single-center studies have addressed the outcome of patients with papillary urothelial neoplasms of low malignant potential. (elsevier.com)
  • Pathologic grading, one of the most important prognostic factors of papillary urothelial neoplasia (PUN) of the urinary bladder , has been revised continuously. (bvsalud.org)
  • Urinary Incontinence The symptoms and causes of urinary incontinence or urge incontinence. (vitals.com)
  • Frequent urinary infections, kidney and bladder stones , and other conditions that cause long-term irritation to the bladder may increase the risk of getting bladder cancer. (thefreedictionary.com)
  • Risk factors for bladder cancer include smoking, family history, prior radiation therapy, frequent bladder infections, and exposure to certain chemicals. (wikipedia.org)
  • These signs and symptoms are not specific to bladder cancer, and may also be caused by non-cancerous conditions, including prostate infections, overactive bladder or cystitis. (wikipedia.org)
  • The bladder is a hollow organ in your lower abdomen that stores urine. (medlineplus.gov)
  • Bladder cancer may cause blood in the urine, pain during urination, frequent urination, the feeling of needing to urinate without being able to, or lower back pain. (medlineplus.gov)
  • A Study Comparing Various Noninvasive Methods of Detecting Bladder Cancer in Urine," BJUI International, Vol. 89, No. 4, 2002, pp. 369-373. (scirp.org)
  • Involuntary discharge of URINE as a result of physical activities that increase abdominal pressure on the URINARY BLADDER without detrusor contraction or overdistended bladder. (bioportfolio.com)
  • The urinary bladder is a hollow muscular organ that stores urine from the kidneys until it is excreted out of the body. (thefreedictionary.com)
  • Two tubes called the ureters bring the urine from the kidneys to the bladder. (thefreedictionary.com)
  • One of the first warning signals of bladder cancer is blood in the urine. (thefreedictionary.com)
  • Bladder cancer characteristically causes blood in the urine, which may be visible or detectable only by microscope. (wikipedia.org)
  • Blood in the urine is the most common symptom in bladder cancer, and is painless. (wikipedia.org)
  • Pseudosarcomatous myofibroblastic proliferation is a descriptive term that designates a group of clinically indolent genitourinary lesions that most commonly arise in the urinary bladder. (ipathology.cn)
  • Many of these neoplasms are succintly described and illustrated in detail in this volume, and some are compared with spontaneously occurring lesions. (springer.com)
  • H. Wang, Y. Guo, X. Zhou and D. Yang, "Urinary Bladder Cancer: The Current and Potential Role of MR Imaging in Non-Distant Metastatic Lesions," Journal of Cancer Therapy , Vol. 4 No. 2, 2013, pp. 504-512. (scirp.org)
  • Smoking Cessation after Bladder Cancer Diagnosis]. (urotoday.com)
  • Our aim was to analyze smoking habits after diagnosis in bladder cancer patients. (urotoday.com)
  • Overactive Bladder Facts about overactive bladder (OAB): risk factors, symptoms & causes. (vitals.com)
  • In rare families, the risk of bladder cancer is inherited. (medlineplus.gov)
  • The risk of bladder cancer increases with age. (thefreedictionary.com)
  • Risk of bladder cancer decreases by 30% within 1-4 years and continues to decrease by 60% at 25 years after smoking cessation. (wikipedia.org)
  • However, former smokers will most likely always be at a higher risk of bladder cancer compared to people who have never smoked. (wikipedia.org)
  • Opium consumption increases the risk of bladder cancer by 3-fold and concurrent use of opium and smoking increases the risk of bladder cancer by 5 times compared to the general population. (wikipedia.org)
  • 187 ...................................... Malignant neoplasm of penis and other male genital organs. (cdc.gov)
  • 189 ...................................... Malignant neoplasm of kidney and other unspecified urinary organs. (cdc.gov)
  • 197 ...................................... Secondary malignant neoplasm of the respiratory and digestive organs. (cdc.gov)
  • 198 ...................................... Secondary malignant neoplasm of other tissue and organs. (cdc.gov)
  • The bladder and rectum could be well separated from the tumor and both organs were spared. (hindawi.com)
  • Given the significant clinicopathologic differences between inflammatory myofibroblastic tumor and pseudosarcomatous myofibroblastic proliferation, our findings provide further support for classification of pseudosarcomatous myofibroblastic proliferation as a distinct clinicopathologic entity, and propose the alternate terminology "pseudosarcomatous myofibroblastic neoplasm of the genitourinary tract. (ipathology.cn)
  • Urinary bladder cancer is the second most common genitourinary malignancy in Westernized countries. (scirp.org)
  • Magnetic resonance imaging (MRI) confirmed the presence of this noninfiltrative solid tumor, between the rectum and the bladder with a thin capsule of low signal in T2. (hindawi.com)
  • Bladder cancer, as of 2018, affected about 1.6 million people globally with 549,000 new cases and 200,000 deaths. (wikipedia.org)
  • In 2018, the highest rate of bladder cancer occurred in Southern and Western Europe followed by North America with rates of 15, 13, and 12 cases per 100,000 people. (wikipedia.org)
  • Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions. (ipathology.cn)
  • The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Urinary Bladder Neoplasms. (centerwatch.com)
  • Hyperthermia and Intravesical Therapy: Emerging One-Two Punch for Bladder Cancer? (cancernetwork.com)
  • Fluorinated Polymer Mediated Transmucosal Peptide Delivery for Intravesical Instillation Therapy of Bladder Cancer. (bioportfolio.com)
  • A single intravesical instillation of Lactobacillus rhamnosus GG is safe in children and adults with neuropathic bladder: A phase Ia clinical trial. (bioportfolio.com)